0001140361-17-018829.txt : 20170508 0001140361-17-018829.hdr.sgml : 20170508 20170508160219 ACCESSION NUMBER: 0001140361-17-018829 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170508 DATE AS OF CHANGE: 20170508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VirnetX Holding Corp CENTRAL INDEX KEY: 0001082324 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 770390628 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33852 FILM NUMBER: 17822182 BUSINESS ADDRESS: STREET 1: 308 DORLA COURT STREET 2: SUITE 206 CITY: ZEPHYR COVE STATE: NV ZIP: 89448 BUSINESS PHONE: (831) 438-8200 MAIL ADDRESS: STREET 1: 308 DORLA COURT STREET 2: SUITE 206 CITY: ZEPHYR COVE STATE: NV ZIP: 89448 FORMER COMPANY: FORMER CONFORMED NAME: PASW INC DATE OF NAME CHANGE: 20001109 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC SOFTWORKS INC DATE OF NAME CHANGE: 19990322 10-Q 1 form10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-33852

VirnetX Holding Corporation

(Exact name of registrant as specified in its charter)

Delaware		77-0390628
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

308 Dorla Court, Suite 206 Zephyr Cove, Nevada		89448
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (775) 548-1785

Former name, former address and former fiscal year, if changed since last report:

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☒
Non-accelerated filer ☐	(Do not check if a smaller reporting company)	Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

The number of shares outstanding of the Registrant’s Common Stock as of May 5, 2017, was 58,144,888.

VIRNETX HOLDING CORPORATION

INDEX

		Page
PART I — FINANCIAL INFORMATION		1
	Item 1 —Financial Statements.	1

	Condensed Consolidated Balance Sheets at March 31, 2017 (unaudited) and December 31, 2016	1
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2017 and 2016 (unaudited)	2
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016 (unaudited)	2
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016 (unaudited)	3
	Notes to Condensed Consolidated Financial Statements	4
	Item 2 —Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

	Item 3 —Quantitative and Qualitative Disclosures About Market Risk	18

	Item 4 —Controls and Procedures	18

PART II —OTHER INFORMATION		19
	Item 1 —Legal Proceedings	19

	Item 1A —Risk Factors	22

	Item 5 —Other Information	30

	Item 6 —Exhibit	31

SIGNATURES		32

Index

PART I — FINANCIAL INFORMATION

ITEM 1- FINANCIAL STATEMENTS.

VIRNETX HOLDING CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share amounts)

	As of March 31, 2017			As of December 31, 2016
ASSETS	(unaudited)
Current assets:
Cash and cash equivalents	$	3,609		$	6,627
Investments available for sale		6,129			9,249
Prepaid expenses and other current assets		868			588
Total current assets		10,606			16,464
Prepaid expenses, non-current		2,279			2,374
Property and equipment, net		24			33
Total assets	$	12,909		$	18,871
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	651		$	1,806
Accrued payroll and related expenses		150			1,522
Income tax liability		401			396
Deferred revenue, current portion		1,500			1,500
Total current liabilities		2,702			5,224

Deferred revenue, non-current portion		2,125			2,500
Total liabilities		4,827			7,724

Commitments and contingencies (Note 4)		—			—

Stockholders’ equity:
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at March 31, 2017 and December 31, 2016, Issued and outstanding: 0 shares at March 31, 2017 and December 31, 2016		—			—
Common stock, par value $0.0001 per share
Authorized: 100,000,000 shares at March 31, 2017 and December 31, 2016, Issued and outstanding: 58,144,888 shares and 58,144,888 shares, at March 31, 2017 and December 31, 2016, respectively		6			6
Additional paid-in capital		170,224			169,391
Accumulated deficit		(162,131	)		(158,238	)
Accumulated other comprehensive loss		(17	)		(12	)
Total stockholders’ equity		8,082			11,147
Total liabilities and stockholders’ equity	$	12,909		$	18,871

The accompanying notes are an integral part of these consolidated financial statements.

Index

VIRNETX HOLDING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in thousands, except per share amounts)

	Three Months Ended
	March 31, 2017			March 31, 2016
Revenue	$	375		$	375
Operating expense:
Research and development		475			450
Selling, general and administrative		3,806			8,543
Total operating expense		4,281			8,993
Loss from operations		(3,906	)		(8,618	)
Interest income, net		17			15
Loss before taxes		(3,889	)		(8,603	)
Provision for income taxes		(5	)		(7	)
Net loss	$	(3,894	)	$	(8,610	)
Basic and diluted loss per share	$	(0.07	)	$	(0.16	)
Weighted average shares outstanding basic and diluted		58,145			54,135

VIRNETX HOLDING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)

(in thousands)

	Three Months Ended
	March 31, 2017			March 31, 2016
Net loss	$	(3,894	)	$	(8,610	)
Other comprehensive gain (loss), net of tax:
Change in equity adjustment from foreign currency translation, net of tax		(1	)		—
Change in unrealized gain (loss) on investments, net of tax		(4	)		9
Total other comprehensive gain (loss) net of tax		(5	)		9
Comprehensive loss	$	(3,899	)	$	(8,601	)

See accompanying notes to condensed consolidated financial statements.

Index

VIRNETX HOLDING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(in thousands)

Cash flows from operating activities:	Three Months Ended March 31, 2017			Three Months Ended March 31, 2016
Net loss	$	(3,894	)	$	(8,610	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		9			6
Amortization of warrant issuance costs		—			(30	)
Stock-based compensation		833			1,234
Changes in assets and liabilities:
Prepaid expenses and other current assets		(185	)		(108	)
Accounts payable and accrued liabilities		(1,155	)		1,643
Accrued payroll and related expenses		(1,372	)		(1,383	)
Related party payable		—			(11	)
Income tax liability		5			—
Deferred revenue		(375	)		(375	)
Net cash used in operating activities		(6,134	)		(7,634	)
Cash flows from investing activities:
Purchase of property and equipment		—			(2	)
Purchase of investments		—			(2,752	)
Proceeds from sale or maturity of investments		3,116			4,116
Net cash provided by investing activities		3,116			1,362
Cash flows from financing activities:
Proceeds from exercise of options		—			20
Proceeds from sale of common stock		—			6,795
Net cash provided by financing activities		—			6,815
Net increase (decrease) in cash and cash equivalents		(3,018	)		543
Cash and cash equivalents, beginning of period		6,627			8,726
Cash and cash equivalents, end of period	$	3,609		$	9,269

Cash paid for income taxes	$	—		$	—

See accompanying notes to condensed consolidated financial statements.

Index

VIRNETX HOLDING CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(Unaudited)

Note 1 — Business Description and Basis of Presentation

VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to license our technology, including GABRIEL Connection Technology™, to various original equipment manufacturers, or OEMs, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence and unified communications markets. Prior to 2012 our revenue was limited to an insignificant amount of software royalties pursuant to the terms of a single license agreement. Since 2012 we had revenues from settlements of patent infringement disputes whereby we received consideration for past sales of licensees that utilized our technology, where there was no prior patent license agreement, as well as license agreement revenues from settlements providing licensing for the continued use of our technology (see “Revenue Recognition”).

Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 49 U.S. and 69 foreign patents with approximately 50 pending patent applications worldwide. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security for Cloud services, Machine-to-Machine (“M2M”), communications in areas including “Smart City,” “Connected Car” and “Connected Home.” All our U.S. and foreign patents and pending patent applications relate generally to securing communications over the internet and as such, cover all our technology and other products. Our issued U.S. and foreign patents expire at various times during the period from 2019 to 2024. Some of our issued patents and pending patent applications were acquired by our principal operating subsidiary, VirnetX, Inc., from Leidos, Inc. (“Leidos”) (f/k/a Science Applications International Corporation, or SAIC) in 2006 and we are required to make payments to Leidos based on cash or certain other values generated from those patents in certain circumstances. The amount of such payments depends upon the type of value generated and certain categories are subject to maximums and other limitations.

Note 2 — Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying Condensed Consolidated Balance Sheet as of March 31, 2017, the Condensed Consolidated Statements of Income for the three months ended March 31, 2017 and 2016, the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016, and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2017, our results of operations for the three months ended March 31, 2017 and 2016, and our cash flows for the three months ended March 31, 2017 and 2016. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.

These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 16, 2017.

Use of Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in our accounting estimates are reasonably likely to occur. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, at the time they are made and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below.

Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

Index

Revenue Recognition

We derive our revenue from patent licensing. The timing and amount of revenue recognized from each licensee depends upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Such agreements may be complex and include multiple elements. These agreements may include, without limitation, elements related to the settlement of past patent infringement liabilities, up-front and non-refundable license fees for the use of patents, patent licensing royalties on covered products sold by licensees, and the compensation structure and ownership of intellectual property rights associated with contractual technology development arrangements. Licensing agreements are accounted for under the Financial Accounting Standards Board (“FASB”) revenue recognition guidance, “Revenue Arrangements with Multiple Deliverables.” This guidance requires consideration to be allocated to each element of an agreement that has stand-alone value using the relative fair value method. In other circumstances, such as those agreements involving consideration for past and expected future patent royalty obligations, after consideration of the particular facts and circumstances, the appropriate recording of revenue between periods may require the use of judgment. In all cases, revenue is only recognized after all the following criteria are met: (1) written agreements have been executed; (2) delivery of technology or intellectual property rights has occurred or services have been rendered; (3) fees are fixed or determinable; and (4) collectability of fees is reasonably assured.

Patent License Agreements: Upon signing a patent license agreement, including licenses entered upon settlement of litigation, we provide the licensee permission to use our patented technology in specific applications. We account for patent license agreements in accordance with the guidance for revenue recognition for arrangements with multiple deliverables, with amounts allocated to each element based on their fair values. We have elected to utilize the leased-based model for revenue recognition with revenue being recognized over the expected period of benefit to the licensee. Under our patent license agreements, we do or expect to typically receive one or a combination of the following forms of payment as consideration for permitting our licensees to use our patented inventions in specific applications and products:

• Consideration for Past Sales: Consideration related to a licensee’s product sales from prior periods may result from a negotiated agreement with a licensee that utilized our patented technology prior to signing a patent license agreement with us or from the resolution of a litigation, disagreement or arbitration with a licensee over the specific terms of an existing license agreement. We may also receive royalty for past sales in connection with the settlement of patent litigation where there was no prior patent license agreement. These amounts are negotiated, typically based upon application of a royalty rate to historical sales prior to the execution of the license agreement. In each of these cases, because delivery has occurred, we record the consideration as revenue when we have obtained a signed agreement, identified a fixed or determinable price, and determined that collectability is reasonably assured.

• Current Royalty Payments: Ongoing royalty payments cover a licensee’s obligations to us related to its sales of covered products in the current contractual reporting period. Licensees that owe these current royalty payments are obligated to provide us with quarterly or semi-annual royalty reports that summarize their sales of covered products and their related royalty obligations to us. We expect to receive these royalty reports subsequent to the period in which our licensees’ underlying sales occurred. As a result, it is impractical for us to recognize revenue in the period in which the underlying sales occur, and, in most cases, we will recognize revenue in the period in which the royalty report is received and other revenue recognition criteria are met due to the fact that without royalty reports from our licensees, our visibility into our licensees’ sales is limited.

• Non-Refundable Up-Front Fees and Minimum Fee Contracts: For licenses that provide for non-refundable up-front or fixed minimum fees over their term, for which we have no future obligations or performance requirements, revenue is generally recognized over the license term. For licenses that provide for fees that are not fixed or determinable, including licenses that provide for extended payment terms and/or payment of a significant portion of the fee after expiration of the license or more than 12 months after delivery, the fees are generally presumed not to be fixed or determinable, and revenue is deferred and recognized as earned, but generally not in advance of collection.

• Non-Royalty Elements: Elements that are not related to royalty revenue in nature, such as settlement fees, expense reimbursement, and damages, if any, are recorded as gain from settlement which is reflected as a separate line item within the operating expenses section in the consolidated statements of operations.

Deferred revenue

In August 2013, we began receiving annual payments on a contract requiring payment to us over 4 years totaling $10,000 ("August 2013 Contract Settlement"). In accordance with our revenue recognition policy we defer and recognize revenue over the life of the contract, but not ahead of collection. We collected the final payment under the contract in 2016 and recognized $375 of revenue, related to the August 2013 Contract Settlement, during the three months ended March 31, 2017 and 2016.

Activity under the August 2013 Contract Settlement was as follows:

Deferred Revenue, December 31, 2016	$	4,000
Less: Amount amortized as revenue		375
Deferred Revenue, March 31, 2017	$	3,625

Index

Earnings Per Share

Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

Concentration of Credit Risk and Other Risks and Uncertainties

Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. A portion of those balances are insured by the Federal Deposit Insurance Corporation. During the three months ended March 31, 2017 we had funds which were uninsured. We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships with major financial institutions. We have not experienced any losses on our deposits of cash and cash equivalents.

Prepaid Expenses

Prepaid expenses at March 31, 2017 include the current portion of prepaid rent for a facility lease for corporate promotional and marketing purposes. From inception, the prepayment totaling $4,000 is being amortized over the 10-year term of the lease. The unamortized non-current portion of the prepayment is included in Prepaid expenses-non-current on the consolidated balance sheet.

Impairment of Long-Lived Assets

On an annual basis, we identify and record impairment losses on long-lived assets when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.

Fair Value of Financial Instruments

Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.

Our financial instruments are stated at amounts that equal, or approximate, fair value. When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique. We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.

Mutual Funds: Valued at the quoted net asset value of shares held.

U.S. government and U.S. agency securities: Fair value measured at the closing price reported on the active market on which the individual securities are traded.

Index

The following tables show the adjusted cost, gross unrealized gains, gross unrealized losses and fair value of our securities by significant investment category as of March 31, 2017 and December 31, 2016.

	March 31, 2017
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	1,947	$	—	$	—		$	1,947	$	1,947	$	—

Level 1:
Mutual funds		1,662		—		—			1,662		1,662		—
U.S. agency securities		6,133		—		(4	)		6,129		—		6,129
		7,795		—		(4	)		7,791		1,662		6,129
Total	$	9,742	$	—	$	(4	)	$	9,738	$	3,609	$	6,129

	December 31, 2016
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	3,432	$	—	$	—		$	3,432	$	3,432	$	—

Level 1:
Mutual funds		3,195		—		—			3,195		3,195		—
U.S. government securities		1,254		—		—			1,254		—		1,254
U.S. agency securities		7,996		2		(3	)		7,995		—		7,995
		12,445		2		(3	)		12,444		3,195		9,249
Total	$	15,877	$	2	$	(3	)	$	15,876	$	6,627	$	9,249

New Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326). The purpose of this ASU is to require a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. We are evaluating the impact this guidance will have on our financial position and statement of operations.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. ASU 2016-09 will be effective for us beginning the first quarter of 2018. We are evaluating the impact of adopting the new stock compensation standard on our consolidated financial statements.

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. We are evaluating the impact this guidance will have on our financial position and statement of operations.

In November 2015, the FASB issued ASU No. 2015-17—Income Taxes (Topic 740). Current GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, this Update requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. For public business entities, the amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. We adopted this update in 2017 and implementation did not have a material impact on our financial position or statement of operations.

Index

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606). This ASU was subsequently amended by ASU No. 2016-10 and 2016-12. As amended, Topic 606 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments create a new Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For a public entity, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are currently evaluating the impact this guidance will have on our financial position and statement of operations.

Note 3 — Income Taxes

We had income tax expense of $5 and $7 for the three months ended March 31, 2017 and 2016, respectively, as a result of minimum tax payments. During the three month period ended March 31, 2017, we had net operating losses (“NOLs”) which generated deferred tax assets for NOL carry-forwards. We provided valuation allowances against the net deferred tax assets including the deferred tax assets for NOL carryforwards. Valuation allowances provided for our net deferred tax assets increased by approximately $1,786 and $3,342 for the three months ended March 31, 2017 and 2016, respectively.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets at March 31, 2017 will not be fully realizable. Accordingly, management has maintained a full valuation allowance against its net deferred tax assets at March 31, 2017. The valuation allowance carried against our net deferred tax assets was approximately $46,000 and $44,000 at March 31, 2017 and December 31, 2016, respectively.

At March 31, 2017, we have federal and state net operating loss carry-forwards of approximately $78,000 and $61,000, respectively, expiring beginning in 2027 and began in 2016 for state, respectively.

Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to net operating losses and tax credits remaining unutilized from such years.

Our policy is to recognize interest and penalties accrued on uncertain tax positions as a component of income tax expense. As of March 31, 2017, we had accrued immaterial amounts of interest and penalties related to the uncertain tax positions.

Note 4 — Commitments And Related Party Transactions

We lease our offices under an operating lease with a third party expiring in October 2017. We recognize rent expense on a straight-line basis over the term of the lease.

We lease the use of an aircraft from K2 Investment Fund LLC (‘‘LLC’’) for business travel for employees of the Company. We incurred approximately $252 and $132 in rental fees and reimbursements to LLC during the three months ended March 31, 2017 and 2016, respectively. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of LLC. On January 31, 2015, we entered into a 12-month non-exclusive lease with LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or LLC with 30 days’ notice. The lease renews on an annual basis unless terminated by the lessor or lessee. Neither party has exercised their termination rights.

Note 5 — Stock Based Compensation

We have a stock incentive plan for employees and others called the “VirnetX Holding Corporation 2013 Equity Incentive Plan”, or the Plan, which has been approved by our stockholders. The Plan provides for the granting of up to 14,124,469 shares of our common stock, including stock options and stock purchase rights (“RSUs”), and will expire in 2024. As of March 31, 2017, 396,221 shares remained available for grant under the Plan. During the three months ending March 31, 2017 we granted options for a total of 25,000 shares with a weighted average grant date fair value of $1.69. During the three months ended March 31, 2016 there were no grants of options or RSUs.

Stock-based compensation expense included in general and administrative expense was $833 and $1,234 for the three months ended March 31, 2017 and 2016, respectively.

As of March 31, 2017, the unrecognized stock-based compensation expense related to non-vested stock options and RSUs was $3,339 and $2,137, respectively, which will be amortized over an estimated weighted average period of approximately 2.54 and 2.20 years, respectively.

Index

Note 6 — Equity

Common Stock

On August 21, 2015, we filed a Universal Shelf Registration Statement with the SEC enabling us to offer and sell from time to time up to $100 million of equity, debt or other types of securities. We also entered into an at-the-market (“ATM”) equity offering sales agreement with Cowen & Company, LLC on August 20, 2015, under which we may offer and sell shares of our common stock having an aggregate value of up to $35 million. We have and expect to use proceeds from this offering for GABRIEL product development and marketing, and general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses. From August 20, 2015 through March 31, 2017, we sold 5,595,650 shares under the ATM. The average sales price per common share was $4.14 and the aggregate proceeds from the sales totaled $23,169 during the period. Sales commissions, fees and other costs associated with the ATM totaled $695.

During the three months ended March 31, 2017, there were no shares sold under the ATM.

Warrants

In 2015 we issued warrants (“Advisor Warrants”) for the purchase of 25,000 shares of common stock at an exercise price of $7 per share, which expire in April 2020. The Advisor Warrants were issued for advisory services provided by a third party. Our Advisor Warrants were recorded at fair value on the issuance date and included in Additional Paid in Capital on our Condensed Consolidated Balance Sheet. The Advisor Warrants are exercisable by the holder, in whole or in part, until expiration, and may also be net-share-settled. Terms of the warrant agreement include no registration requirements for the underlying common stock and there are no anti-dilution provisions. The fair value at issuance of the warrants was recorded in Prepaid Expenses and Other Current Assets, and was amortized over the twelve-month life of the service contract, with the expense included in Selling, General and Administrative Expense in our Condensed Consolidated Statements of Operations.

The fair value of the Advisor Warrants at the issuance date of $121 was estimated utilizing the Black-Scholes valuation model with the following assumptions: (i) dividend yield on our common stock of 0 percent, (ii) expected stock price volatility of 87.5 percent, (iii) a risk-free interest rate of 1.33 percent, and (iv) an expected warrant term of 5 years.

Information about warrants outstanding during the three months ended March 31, 2017 follows:

Original Number of Warrants Issued		Exercise Price per Common Share		Exercisable at December 31, 2016		Became Exercisable		Exercised		Terminated / Cancelled / Expired		Exercisable at March 31, 2017		Expiration Date
	25,000	$	7.00		25,000		—		—		—		25,000	April 2020
					25,000		—		—		—		25,000

Index

Note 7 — Litigation

We have nine intellectual property infringement lawsuits pending in the United States District Court for the Eastern District of Texas, Tyler Division, and United States Court of Appeals for the Federal Circuit (“USCAFC”).

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED)

On March 30, 2015, the United States Court for the Eastern District of Texas, Tyler Division, issued an order finding substantial overlap between the remanded portions of the Civil Action Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.), and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. The jury trial in this case was held on January 25, 2016. On February 4, 2016, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us $625.6 million in a verdict against Apple Inc. for infringing four of our US patents, marking it the second time a federal jury has found Apple liable for infringing VirnetX’s patented technology. The verdict includes royalties awarded to us based on an earlier patent infringement finding (Case 6:10-CV-00417-LED) against Apple. The jury found that Apple’s modified VPN On-Demand, iMessage and FaceTime services infringed VirnetX’s patents and that Apple’s infringement was willful. In addition to determining the royalty owed by Apple for its prior infringement, this verdict also includes an award based on the jury’s finding that Apple’s modified VPN On Demand, iMessage and FaceTime services have continued to infringe VirnetX’s patents. The post-trial hearing was held on May 25, 2016 in the United States Court for the Eastern District of Texas, Texarkana Division. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases (Case No. 6:10-cv-417, Docket No. 878 (“Apple I case”); Case No. 6:12-cv-855, Docket No. 220 (“Apple II case”)), ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II case will be retried after Apple I case. Events and developments subsequent to the order from the court are described to support Apple I and Apple II matters.

VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (“Apple I”)

On August 11, 2010, we initiated a lawsuit by filing a complaint against Aastra USA. Inc. (“Aastra”), Apple, Cisco Systems, Inc. (“Cisco”), and NEC Corporation (“NEC”) in the United States District Court for the Eastern District of Texas, Tyler Division, pursuant to which we alleged that these parties infringe on certain of our patents. We sought damages and injunctive relief. Aastra and NEC agreed to sign license agreements with us and we agreed to drop all the accusations of infringement against them. At the pre-trial hearing, the judge decided to conduct separate jury trial for each defendant, and try only the case against Apple on the scheduled trial date. The jury trial of our case against Cisco was held on March 4, 2013. The jury in our case against Cisco came back with a verdict of non-infringement also determined that all our patents-in-suit patents are not invalid. Our motions for a new trial and Cisco’s infringement of certain VirnetX patents were denied and the case against Cisco was closed.

The jury trial of our case against Apple was held on October 31, 2012. On November 6, 2012, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us over $368 million in a verdict against Apple for infringing four of our patents. On February 26, 2013, the court issued its Memorandum Opinion and Order regarding post-trial motions resulting from the prior jury verdict denying Apple’s motion to reduce the damages awarded by the jury for past infringement. The Court further denied Apple’s request for a new trial on the liability and damages portions of the verdict and granted our motions for pre-judgment interest, post-judgment interest, and post-verdict damages to date. The Court ordered that Apple pay $34 thousand in daily interest up to final judgment and $330 thousand in daily damages for infringement up to final judgment for certain Apple devices included in the verdict. The Court denied our request for a permanent injunction and severed the future infringement portion into its own separate proceedings under Case 6:13-CV-00211-LED.

On July 3, 2013, Apple filed an appeal of the judgment dated February 27, 2013 and order dated June 4, 2013 denying Apple’s motion to alter or amend the judgment to the USCAFC. On September 16, 2014, USCAFC issued their opinion, affirming the jury’s finding that all 4 of our patents are valid, confirming the jury’s finding of infringement of VPN on Demand under many of the asserted claims of our ‘135 and ‘151 patents, and confirming the district’s court’s decision to allow evidence concerning our licenses and royalty rates in connection with the determination of damages. In its opinion, the USCAFC also vacated the jury’s damages award and the district court’s claim construction with respect to parts of our ‘504 and ‘211 patents and remanded the damages award and determination of infringement with respect to FaceTime –for further proceedings consistent with its opinion. On October 16, 2014, we filed a petition with the USCAFC, requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision concerning VirnetX’s litigation against Apple Inc. On December 16, 2014, USCAFC denied our petition requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision and remanded the case back to the Eastern District of Texas, Tyler Division, for further proceedings consistent with its opinion. On February 25, 2015, USCAFC granted Apple’s motions to lift stay of proceedings and vacate Case 6:13-CV-00211-LED. On March 30, 2015, the court issued an order finding substantial overlap between the remanded portions of this case and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case.

Index

On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case. The jury trial in this case was held on September 26, 2016. On September 30, 2016, a Jury in the United States Court for the Eastern District of Texas, Tyler Division, in the case VirnetX Inc., et al. v. Apple Inc., No. Apple I, has awarded VirnetX $302.4 million in a verdict against Apple for infringing four VirnetX patents, marking the third time a federal jury has found Apple liable for infringing VirnetX’s patented technology.

The verdict includes royalties awarded to VirnetX, for unresolved issues in the Apple I case, remanded back from the USCAFC, related to (1) damages owed to VirnetX for infringement by Apple’s original VPN-on-Demand (VOD) and (2) the alleged infringement by Apple’s original FaceTime product, under the new claim construction of “secure communication link” pertaining to the ’504 and ’211 patents by the USCAFC, and the damages associated with that infringement. The hearing on all the post-trial motions was held on November 22, 2016. We are currently awaiting the court ruling and final judgement in this case.

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)

On November 6, 2012, we filed a new complaint against Apple in the United States District Court for the Eastern District of Texas, Tyler Division for willfully infringing four of our patents, U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151, and seeking both an unspecified amount of damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Due to their release dates, these products were not included in the previous lawsuit that concluded with a Jury verdict on November 6, 2012 that was subsequently upheld by the United States District Court for the Eastern District of Texas, Tyler Division, on February 26, 2013. On July 1, 2013, we filed a consolidated and amended complaint to include U.S. Patent No. 8,051,181 and consolidate Civil Action No. 6:11-cv-00563-LED. On August 27, 2013, we filed an amended complaint including allegations of willful infringement related to U.S. Patent No. 8,504,697 seeking both damages and injunctive relief. The Markman hearing in this case was held on May 20, 2014 and on August 8, 2014, issued its Markman Order, denying Apple’s motion for summary judgment of indefiniteness, in which Apple alleged that some of the disputed claims terms in the patents asserted by us were invalid for indefiniteness. In a separate order, the court granted in part and denied in part our motion for partial summary judgment on Apple’s invalidity counterclaims, precluding Apple from asserting invalidity as a defense against infringement of the claims that were tried before a jury in our prior litigation against Apple (VirnetX vs. Cisco et. al., Case 6:10-CV-00417-LED). The jury trial in this case was scheduled for October 13, 2015. On March 30, 2015, the court issued an order finding substantial overlap between this case and the remanded portions of Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case. We are awaiting court order setting the date for a new jury trial in Apple II case.

VirnetX Inc. v. Apple, Inc. (Case 15-1934)

On July 10, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the United States Patent and Trademark Office, Patent Trial and Appeal Board (“PTAB”) in IPR2014-00237 and IPR2014-00238, related to U.S. Patent No. 8,504,697. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00238. We are currently evaluating our options in this case.

VirnetX Inc. v. Apple, Inc. (Case 16-1211)

On September 28, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2014-00403 and IPR2014-00404 and on October 22, 2015 for IPR2014-00481 and IPR2014-00482 involving our U.S. Patent Nos. 7,188,180, and 7,987,274. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00403 and IPR2014-00481. We are currently evaluating our options in this case.

VirnetX Inc. v. Apple, Inc. (Case 16-1480)

On November 30, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in inter-partes reexamination no. 95/001,949 related to U.S. Patent No. 8,051,181. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on certain grounds. We are currently evaluating our options in this case.

VirnetX Inc. v. Apple, Inc. (case 16-119)

On March 4, 2016, we filed a petition for writ of mandamus with the USCAFC, requesting the USCAFC’s intervention to revoke the PTAB’s decision joining Apple to IPR2015-01046 and IPR2015-01047, related to U.S. Patent Nos. 6,502,135 and 7,490,151. On March 18, 2016, the USCAFC denied the petition without prejudice to us raising the arguments on appeal after the PTAB’s final decisions. We are currently evaluating our options in this case.

VirnetX Inc. v. Apple, Inc. (Case 17-1131)

On October 31, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-00810, IPR2015-00812, on November 9, 2016 for IPR2015-00811, and on November 28, 2016 for IPR2015-00866, IPR2015-00868, IPR2015-00870, IPR2015-00871 involving our U.S. Patent Nos.8,868,705, 8,850,009, 8,458,341, 8,516,131, and 8,560,705. These appeals have been consolidated.

Index

VirnetX Inc. v. The Mangrove Partners (Case 17-1368)

On December 16, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-01046, and on December 20, 2016 for IPR2015-1047, involving our U.S. Patent Nos. 6,502,135, and 7,490,151. These appeals also involve Apple, Inc. and one of them involves Black Swamp IP, LLC.

One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are worth pursuing, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we will prevail on such potential claims. In addition, bringing a lawsuit may lead to potential counterclaims which may preclude our ability to commercialize our initial products, which are currently in development. Currently, we are not a party to any other pending legal proceedings, and are not aware of any proceeding threatened or contemplated against us by any governmental authority or other party.

Index

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Note About Forward-Looking Statements

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may appear throughout this report, including without limitation, the following sections: “Management’s Discussion and Analysis,” and “Risk Factors.” These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part II, Item 1A of this Form 10-Q). We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

Company Overview

We are an Internet security software and technology company with patented technology for secure communications including 4G Long Term Evolution (“LTE”), security. Our software and technology solutions, including our Secure Domain Name Registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and provide the security platform required by next-generation Internet-based applications such as instant messaging, or IM, voice over Internet Protocol, (“VoIP”), mobile services, streaming video, file transfer, remote desktop and Machine-to-Machine (“M2M”) communications. Our technology generates secure connections on a ‘‘zero-click’’ or ‘‘single-click’’ basis, significantly simplifying the deployment of secure real-time communication solutions by eliminating the need for end-users to enter any encryption information. Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 49 U.S. and 69 foreign patents with approximately 50 pending patent applications worldwide. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security for Cloud services, M2M communications in new initiatives including ‘‘Smart City’’, ‘‘Connected Car’’ and ‘‘Connected Home’’ that would connect everything from social services and citizen engagement to public safety, transportation and economic development to the internet to enable more productivity, features and efficiency in our everyday lives. The subject matter of all our U.S. and foreign patents and pending applications relates generally to securing communication over the internet, and as such covers all our technology and other products. Our issued U.S. and foreign patents expire at various times during the period from 2019 to 2024. Some of our issued patents and pending patent applications were acquired by our principal operating subsidiary; VirnetX, Inc., from Leidos, Inc. (“Leidos”) (f/k/a Science Applications International Corporation, or SAIC) in 2006 and we are required to make payments to Leidos, based on cash or certain other values generated from those patents. The amount of such payments depends upon the type of value generated, and certain categories are subject to maximums and other limitations.

Our product Gabriel Secure Communication Platform™, unlike other collaboration and communication products and services on the market today, does not require access to user’s confidential data and reduces the threat of hacking and data mining. It enables individuals and organizations to maintain complete ownership and control over their personal and confidential data, secured within their own private network, while enabling authorized secure encrypted access from anywhere at any time. Our Gabriel Collaboration Suite™ is a set of applications that run on top of our Gabriel Secure Communication Platform™. It enables seamless and secure cross-platform communications between user’s devices that have our software installed. Our Gabriel Collaboration Suite™ is available for download and free trial, for Android, iOS, Windows, Linux and Mac OS X platforms, at http://www.gabrielsecure.com/. We continue to enhance our products and add new functionality to our products. We will provide updates to new and existing customers as they are released to the public. Over 80 small and medium businesses have installed our Gabriel Secure Communication Platform™ and Gabriel Collaboration Suite™ products in their corporate networks. We seek to expand our customer base with targeted promotions and direct sales initiatives.

We have executed a number of patent and technology licenses and intend to seek further licensees for our technology, including our GABRIEL Connection Technology™ to original equipment manufacturers, or OEMs, of chips, servers, smart phones, tablets, e-Readers, laptops, net books and other devices, within the IP-telephony, mobility, fixed-mobile convergence and unified communications markets including 4G/LTE Advanced.

We have submitted a declaration with the 3rd Generation Partnership Project, or 3GPP, identifying a group of our patents and patent applications that we believe are or may become essential to certain developing specifications in the 3GPP LTE, SAE project. We have agreed to make available a non-exclusive patent license under fair, reasonable and non-discriminatory, or FRAND, terms and conditions, with compensation to 3GPP members desiring to implement the technical specifications identified by us. We believe that we are positioned to license our essential security patents to 3GPP members as they move into deploying 4G/LTE Advanced devices and solutions.

Index

We have an ongoing Gabriel Licensing Program under which we offer licenses to a portion of our patent portfolio, technology and software, including our secure domain name registry service, to domain infrastructure providers, communication service providers as well as to system integrators. Our GABRIEL Connection Technology™ License is offered to OEM customers who want to adopt the GABRIEL Connection Technology™ as their solution for establishing secure connections using secure domain names within their products. We have developed GABRIEL Connection Technology™ Software Development Kit (SDK) to assist with rapid integration of these techniques into existing software implementations with minimal code changes and include object libraries, sample code, testing and quality assurance tools and the supporting documentation necessary for a customer to implement our technology. Customers who want to develop their own implementation of the VirnetX patented techniques for supporting secure domain names, or other techniques that are covered by our patent portfolio for establishing secure communication links, can purchase a patent license. The number of patents licensed, and therefore the cost of the patent license to the customer, will depend upon which of the patents are used in a particular product or service. These licenses will typically include an initial license fee, as well as an ongoing royalty.

We have signed Patent License Agreements with Avaya Inc., Aastra USA, Inc., Microsoft Corporation, Mitel Networks Corporation, NEC Corporation and NEC Corporation of America, Siemens Enterprise Communications GmbH & Co. KG, and Siemens Enterprise Communications Inc. to license certain of our patents, for a one-time payment and/or an ongoing royalty for all future sales through the expiration of the licensed patents with respect to certain current and future IP-encrypted products. We have engaged IPVALUE Management Inc. to assist us in commercializing our portfolio of patents on securing real-time communications over the Internet. Under the multi-year agreement, IPVALUE is expected to originate and assist us with negotiating transactions related to patent licensing worldwide with respect to certain third parties.

We believe that the market opportunity for our software and technology solutions is large and expanding as secure domain names are now an integral part of securing the next generation 4G/LTE Advanced wireless networks and M2M communications in areas including Smart City, Connected Car and Connected Home. We also believe that all 4G/LTE Advanced mobile devices will require unique secure domain names and become part of a secure domain name registry.

We intend to license our patent portfolio, technology and software, including our secure domain name registry service, to domain infrastructure providers, communication service providers as well as to system integrators. We intend to seek further license of our technology, including our GABRIEL Connection Technology™ to enterprise customers, developers and original equipment manufacturers, or OEMs, of chips, servers, smart phones, tablets, e-Readers, laptops, net books and other devices, within the IP-telephony, mobility, fixed-mobile convergence and unified communications markets including 4G/LTE.

Our employees include the core development team behind our patent portfolio, technology and software. This team has worked together for over ten years and is the same team that invented and developed this technology while working at Leidos, Inc. (‘‘Leidos’’). Leidos is a FORTUNE 500® scientific, engineering and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure and health. The team has continued its research and development work started at Leidos, and expanded the set of patents we acquired in 2006 from Leidos, into a larger portfolio of over 110 U.S. and international patents and with over 75 pending applications. This portfolio now serves as the foundation of our licensing business and planned service offerings and is expected to generate the majority of our future revenue in license fees and royalties. We intend to continue our research and development efforts to further strengthen and expand our patent portfolio.

We intend to continue using an outsourced and leveraged model to maintain efficiency and manage costs as we grow our licensing business by, for example, offering incentives to early licensing targets or asserting our rights for use of our patents. We also intend to expand our design pilot in participation with leading 4G/LTE companies (domain infrastructure providers, chipset manufacturers, service providers and others) and build our secure domain name registry.

New Accounting Pronouncements

Index

Results of Operation

Three Months Ended March 31, 2017

Compared with Three Months Ended March 31, 2016

(in thousands, except per share amounts)

Revenue

For the three months ended March 31, 2017 and 2016 we recognized revenue of $375 from non-refundable up-front fees earned during the period. In August 2013, we began receiving annual payments on a contract which totaled $10,000 over the 4-year period. Revenues from these fees are deferred and recognized as revenue when earned in accordance with our revenue recognition policy, but not in advance of collection.

Research and Development Expenses

Our research and development expenses increased by $25 to $475 for the three months ended March 31, 2017, from $450 for the three months ended March 31, 2016. This increase was primarily due to increase in wages and health insurance costs for our employees.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses decreased by $4,737 to $3,806 for the three months ended March 31, 2017, from $8,543 for the three months ended March 31, 2016. The decrease is primarily due to a decrease in legal fees of $4,622 associated with our current patent infringement actions.

Other Income and Expenses

Interest income increased by $2 to $17 for the three months ended March 31, 2017, from $15 for the comparable 2016 period.

Liquidity and Capital Resources

As of March 31, 2017, our cash and cash equivalents totaled approximately $3,609 and our short-term investments totaled approximately $6,129, compared to cash and cash equivalents of approximately $6,627 and short-term investments of approximately $9,249 at December 31, 2016, respectively. Working capital was $7,904 at March 31, 2017, and $11,240 at December 31, 2016. The decrease in cash and investments during the three months ended March 31, 2017 was primarily attributed to costs incurred for legal expenses in defense of our patent infringement actions and the loss incurred during the period.

We expect that our cash and cash equivalents and short-term investments as of March 31, 2017, as well as our ability to receive cash from sales of common shares under the ATM and the Universal Shelf Registration Statement, described below, will be sufficient to fund our current level of selling, general and administration costs, including legal expenses and provide related working capital for the foreseeable future. Over the longer term, we expect to derive the majority of our future revenue from license fees and royalties associated with our patent portfolio, technology, software and secure domain name registry in the United States and other markets around the world.

Universal Shelf Registration Statement and ATM Offering

On August 21, 2015, we filed a universal shelf registration statement with the U.S. Securities and Exchange Commission enabling us to offer and sell from time to time up to $100 million of equity, debt or other types of securities. We also entered into an at-the-market (“ATM”) equity offering sales agreement with Cowen & Company, LLC on August 20, 2015, under which we may offer and sell shares of our common stock having an aggregate value of up to $35 million. We expect to use proceeds from this offering for GABRIEL product development and marketing, and general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

Income Taxes

Index

Contractual Obligations

There have been no material changes to the contractual obligations disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Off-Balance Sheet Arrangements

None.

Index

ITEM 3 — QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Interest Rate Risk

We invest our excess cash primarily in highly liquid instruments including time deposits, money market, and corporate debt securities. We seek to limit the amount of our credit exposure to any one issuer.

Investments in fixed rate instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates. Due in part to these factors, our income from investments may decrease in the future.

We considered the historical volatility of short-term interest rates and determined that it was reasonably possible that an adverse change of 100 basis points could be experienced in the near term but would have an immaterial impact in the fair value of our marketable securities, which generally mature within one year of March 31, 2017.

Other Market Risks

We considered the historical volatility of our stock prices and determined that it was reasonably possible that the fair market value of our stock price could increase or decrease substantially in the near term and could have a material impact to our consolidated balance sheets and statement of operations with respect to future stock-based compensation costs and other equity transactions.

ITEM 4 — CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of March 31, 2017.

The purpose of this evaluation was to determine whether as of March 31, 2017 our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in our filings with the SEC, (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2017, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Index

PART II — OTHER INFORMATION

ITEM 1 — LEGAL PROCEEDINGS

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED)

VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (“Apple I”)

Index

VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)

VirnetX Inc. v. Apple, Inc. (Case 15-1934)

VirnetX Inc. v. Apple, Inc. (Case 16-1211)

VirnetX Inc. v. Apple, Inc. (Case 16-1480)

VirnetX Inc. v. Apple, Inc. (case 16-119)

Index

VirnetX Inc. v. Apple, Inc. (Case 17-1131)

VirnetX Inc. v. The Mangrove Partners (Case 17-1368)

Index

ITEM 1A — RISK FACTORS

Our operations and financial results are subject to various risks and uncertainties, including those described below, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common and capital stock. You should carefully consider the following material risks in addition to the other information set forth in this Quarterly Report on Form 10-Q, as well as our Annual Form 10-K filed March 16, 2017 before making any investment in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of these risk factors occur, you could lose substantial value or your entire investment in our shares.

Risks Related to Our Business and Our Financial Reporting

We are involved and will continue to be involved in litigation defending our patent portfolio, which can be time-consuming and costly and we cannot anticipate the results.

We spend a significant amount of our financial and management resources to pursue our current litigation. We believe that this litigation and others that we may pursue in the future could continue for years and consume significant financial and management resources. The counterpart to our litigation includes large, well-financed companies with substantially greater resources than us. We cannot assure you that any of our current or future litigation matters will result in a favorable outcome for us. In addition, even if we obtain favorable interim rulings or verdicts, they may be inconsistent with the ultimate resolution of the dispute. Also, we cannot assure you that we will not be exposed to claims or sanctions against us which may be costly or impossible for us to defend. Unfavorable or adverse outcomes may result in losses, exhaustion of financial resources or other adverse effects, which could encumber our ability to develop and commercialize our products.

We may seek additional capital to support our business growth, and this capital will be dilutive, may cause our stock price to drop or may not be available on acceptable terms, if at all.

We may seek additional capital to support our business growth or to respond to business opportunities, challenges or unforeseen circumstances, including sales under our ATM or our Universal Shelf Registration Statement. Our ability to obtain additional capital, if and when required, will depend on our business plans, investor demand, our operating performance, the condition of the capital markets, the terms of our current contractual obligations and other factors. If we raise additional funds through the issuance of equity, equity-linked or debt securities, including those under our ATM or our Universal Shelf Registration Statement, those securities may have rights, preferences, or privileges senior to the rights of our common stock, and our existing stockholders may experience dilution. Additionally, we are unable to predict the success of our current ATM offering. Sales of a substantial number of shares of our common stock in the public market, the perception that these sales or other financings might occur, could depress the market price of our common stock and could also impair our ability to raise capital through the sale of additional equity securities. If we issue debt securities or incur indebtedness, the incurrence of indebtedness would result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to obtain additional capital, or are unable to obtain additional capital on satisfactory terms, our ability to continue to support our business growth or to respond to business opportunities, challenges, or other circumstances could be adversely affected, and our business may be harmed.

We may not be able to capitalize on market opportunities related to our licensing strategy or our patent portfolio.

Our business strategy includes licensing our patents and technology to other companies in order to reach a larger end-user base than we could reach through direct sales and marketing efforts; as such, our business strategy and revenues will depend on intellectual property licensing fees and royalties for the majority of our revenues. We currently derive minimal revenue from licensing activities and we cannot assure you that we will successfully capitalize on our market opportunities or that our current business strategy will succeed. Factors that may affect our ability to execute our current business strategy include, but are not limited to, the following:

•

Although to date we have entered into a limited number of settlement and license agreements, we may not be successful in entering into further licensing relationships, or if we are successful in entering into such relationships, the acquisition of them may be expensive, and they, as well as our existing settlement and license agreements may not generate the financial results we expect;

•

Third parties may challenge the validity of our patents;

•

The pendency of our various litigations may cause potential licensees not to do business with us;

•

We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and

•

It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.

Index

If we are not able to adequately protect our patent rights, our business would be negatively impacted.

We believe our patents are valid, enforceable and valuable. Notwithstanding this belief, third parties may make claims of infringement or invalidity claims with respect to our patents and such claims could give rise to material cost for defense or settlement or both, jeopardize or substantially delay a successful outcome of litigation we are or may become involved in, divert resources away from our other activities, limit or cease our revenues related to such patents, or otherwise materially and adversely affect our business. Similar challenges could also prevent us from obtaining additional patents in the future. Additionally, several of our patents are currently, and other patents may in the future be, subject to USPTO post-grant inter partes review proceedings (“IPR”) which may result in all or part of these patents being invalidated or the claims of our patents being limited. Unfavorable or adverse outcomes in our litigation or IPRs may result in losses, exhaustion of financial resources, reduction in our ability to enforce our intellectual property rights, or other adverse effects, which could encumber our ability to develop and commercialize our products. Even if we are successful in enforcing our intellectual property rights, our patents may not ultimately provide us with any competitive advantages and may be less valuable than we currently expect. These risks may be heightened in countries other than the United States where laws regarding patent protection are less developed, and may be negatively affected by the fact that legal standards in the United States and elsewhere for protection of intellectual property rights in Internet-related businesses are uncertain and still evolving. In addition, there are a significant number of United States and foreign patents and patent applications in our areas of interest, and we expect that significant litigation in these areas will continue, and will add uncertainty to the value of certain patents and other intellectual property rights in our areas of interest. If we are unable to protect our intellectual property rights or otherwise realize value from them, our business would be negatively affected.

We can provide no assurances that the licensing of our essential security patents under FRAND will be successful.

At the request of the European Telecommunications Standards Institute or “ETSI”, and the Alliance for Telecommunications Industry Solutions or “ATIS”, we agreed to update our licensing declaration to ETSI and ATIS under their respective Intellectual Property Rights or “IPR” policies. This was in response to our Statement of Patent Holder identifying a group of our patents and patent applications that we believe are or may become essential to certain developing specifications in the 3rd Generation Partnership Project (3GPP) Long Term Evolution or “LTE”, Systems Architecture Evolution or “SAE” project. We will make available a non-exclusive patent license under FRAND (fair, reasonable and non-discriminatory terms and conditions, with compensation) for the patents identified by us that are or become essential, to applicants desiring to implement the Technical Specifications identified by us, as set forth in the updated licensing declaration under the ATIS and ETSI IPR policies. Our licensing declarations under the ATIS and ETSI IPR policies may limit our flexibility in determining royalties and license terms for certain of our patents. Consequently, we cannot assure you that the licensing of the essential security patents will be successful or that third parties will be willing to enter into licenses with us on reasonable terms or at all, which could have an adverse effect on our business and harm our competitive position.

Because our business is conducted or expected to be conducted in an environment that is subject to rapid change, we may be subject to various developments in regulation, law and consumer preferences to which we may not be able to adapt successfully.

The current regulatory environment for our products and services remains unclear. We can give no assurance that our planned product offerings will be in compliance with laws and regulations of local, state, United States federal or foreign authorities. Further, we can give no assurance that we will not unintentionally violate such laws or regulations or that such laws or regulations will not be modified, or that new laws or regulations will be enacted in the future which would cause us to be in violation of such laws or regulations. For example, Voice-Over-Internet Protocol or “VoIP” services are not currently subject to all of the same regulations that apply to traditional telephony, but it is possible that similar regulations may be applied to VoIP in the future and that these could result in substantial costs to us which could adversely affect the marketability of our products and planned products related to VoIP. For further example, the use of the Internet and private Internet Protocol or “IP” networks for communication is largely unregulated within the United States, but may become regulated in the future; also, several foreign governments have enacted measures that could restrict or prohibit voice communications services over the Internet or private IP networks.

Our business depends on the growth of instant messaging, VoIP, mobile services, streaming video, file transfer and remote desktop and other next-generation Internet-based applications. A decline in the use of these applications due to complexity or cost of these applications relative to alternate traditional or newly developed communications channels, or development of alternative technologies, could cause a material decline in the number of users in these areas.

More aggressive domestic or international regulation of the Internet in general, and Internet telephony providers and services specifically may materially and adversely affect our business, financial condition, operating results and future prospects.

Our exposure to outside influences beyond our control, including new legislation, court rulings or actions by the United States Patent and Trademark Office, could adversely affect our licensing and enforcement activities and results of operations.

Our licensing and enforcement activities are subject to numerous risks from outside influences, including the following:

•

New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has recently modified some tests used by the United States Patent and Trademark Office or “USPTO” in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, the United States recently enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act or “AIA”, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents.

•

More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO.

Index

•

Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer.

•

As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.

If we experience security breaches, we could be exposed to liability and our reputation and business could suffer.

We expect to retain certain confidential and proprietary customer information in our secure data centers and secure domain name registry, as well as personal data and other confidential and proprietary information relating to our business. It will be critical to our business strategy that our facilities and infrastructure remain secure and are perceived by the marketplace to be secure. Our secure domain name registry operations will also depend on our ability to maintain our computer and telecommunications equipment in effective working order and to reasonably protect our systems against interruption, and potentially depend on protection by other registrars in the shared registration system. The secure domain name servers that we will operate will be critical hardware to our registry services operations. Therefore, we expect to have to expend significant time and money to maintain or increase the security of our products, facilities and infrastructure. Security technologies are constantly being tested by computer professionals, academics and “hackers.” Advances in computer capabilities and the techniques for attacking security solutions, new discoveries in the field of cryptography or other events or developments could result in compromises or breaches of our security measures and could make some or all our products obsolete or unmarketable. Likewise, if any of our products are found to have significant security vulnerabilities, then we may need to dedicate engineering and other resources to eliminate the vulnerabilities and to repair or replace products already sold or licensed to our customers. Despite our security measures, our infrastructure may be vulnerable to physical break-ins, computer viruses, attacks by hackers or similar disruptive problems. It is possible that we may have to expend additional financial and other resources to address such problems. Any physical or electronic break-in or other security breach or compromise of the information stored at our secure data centers and domain name registration systems, including any compromise due to human error or employee or contractor malfeasance, may jeopardize the security of information stored on our premises or in the computer systems and networks of our customers. In such an event, we could face significant liability and customers could be reluctant to use our services. Additionally, any such data security incident, or the perception that one has occurred could also result in adverse publicity and therefore adversely affect the market’s perception of the security of electronic commerce and communications over IP networks as well as the security or reliability of our services.

A security breach could require a substantial level of financial resources to rectify and could result in a claim and investigation that cause us to incur substantial fines, penalties, or other liability and related legal and other costs. Any actual or perceived security breach may also harm our reputation and make it more difficult or impossible for us to successfully market to others. Any of the foregoing matters could harm our operating results and financial condition.

Privacy and data security concerns, and data collection and transfer restrictions and related domestic or foreign regulations may limit the use and adoption of our solutions and adversely affect our business.

Personal privacy, information security, and data protection are significant issues in the United States, Europe and many other jurisdictions where we have operations or offer our products. The regulatory framework governing the collection, processing, storage and use of confidential and proprietary business information and personal data is rapidly evolving. The U.S. federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data.

Further, many foreign countries and governmental bodies, including the European Union, or EU, where we conduct business, have laws and regulations concerning the collection and use of personal data obtained from their residents or by businesses operating within their jurisdiction. These laws and regulations often are more restrictive than those in the United States. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure and security of data that identifies or may be used to identify or locate an individual, such as names, email addresses and, in some jurisdictions, Internet Protocol, or IP, addresses.

We also expect that there will continue to be new proposed laws, regulations and industry standards concerning privacy, data protection and information security in the United States, the EU, and other jurisdictions. For example, the European Commission recently adopted a General Data Protection Regulation, effective in May 2018, that will supersede current EU data protection legislation, impose more stringent EU data protection requirements, and provide for greater penalties for noncompliance. We cannot yet determine the impact such future laws, regulations and standards may have on our business. Such laws and regulations are often subject to differing interpretations, may be inconsistent among jurisdictions, and may be alleged to be inconsistent with our current or future practices. Additionally, we may be bound by contractual requirements applicable to our collection, use, processing, and disclosure of various types of data, including personal data, and may be bound by, or voluntarily comply with, self-regulatory or other industry standards relating to these matters. These and other requirements could reduce demand for our products, increase our costs, impair our ability to grow our business, or restrict our ability to store and process data or, in some cases, impact our ability to offer our service in some locations and may subject us to liability. Any failure or perceived failure to comply with applicable laws, regulations, industry standards, and contractual obligations may adversely affect our business. Further, in view of new or modified federal, state or foreign laws and regulations, industry standards, contractual obligations and other legal obligations, or any changes in their interpretation, we may find it necessary or desirable to fundamentally change our business activities and practices or to expend significant resources to modify our product and otherwise adapt to these changes. We may be unable to make such changes and modifications in a commercially reasonable manner or at all, and our ability to develop new products and features could be limited.

The costs of compliance with and other burdens imposed by laws, regulations and standards may limit the use and adoption of our service and reduce overall demand for it, or lead to significant fines, penalties or liabilities for any noncompliance. Privacy, information security, and data protection concerns, whether valid or not valid, may inhibit market adoption of our platform, particularly in certain industries and foreign countries.

Index

We expect that we will experience long and unpredictable sales cycles, which may impact our operating results.

We expect that our sales cycles will be long and unpredictable due to several factors, including but not limited to:

•

The need to educate potential customers about our patent rights and our product and service capabilities;

•

Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;

•

Our customers’ budgetary constraints;

•

The timing of our customers’ budget cycles;

•

Delays caused by customers’ internal review processes; and

•

Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.

If we are unable to expand our revenue sources or establish, sustain, grow or replace relationships with a diversified customer base, our revenues may be limited.

We currently generate revenue from a limited number of customers that have entered into Settlement and License Agreements. Although our GABRIEL Collaboration Suite is not currently generating revenue, it will take time for us to grow our installed user base and generate new customers. Additionally, there is no guarantee that we will be able to derive revenue from new customers, sustain or increase revenue from existing customers or replace customers from whom we currently generate revenue. As a result, our revenue may be limited or static.

We have limited technical resources and are at an early stage in the development and commercialization of our GABRIEL Collaboration Suite.

We currently have only one commercial product, the GABRIEL Collaboration Suite. As such, we have a small technical team, which may limit our ability to rapidly adapt our product to customer requirements or add new product features to maintain our competitive edge and drive adoption. Based on the scale of our technical resources, our limited historical financial data upon which to base our projected revenue or planned operating expenses related to our GABRIEL Collaboration Suite, we may not be able to effectively:

•

generate revenues or profit from product sales;

•

drive adoption of our products;

•

attract and retain customers for our products;

•

provide appropriate levels of customer training and support for our products;

•

implement an effective marketing strategy to promote awareness of our products;

•

focus our research and development efforts in areas that generate returns on our efforts;

•

anticipate and adapt to changes in our market; or

•

protect our products from any system failures or other breaches.

In addition, a high percentage of our expenses are and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, our losses may be greater than expected and our operating results will suffer.

Our products are highly technical and may contain undetected errors, which could cause harm to our reputation and adversely affect our business.

Our products are highly technical and complex and, when deployed, may contain errors or defects. Despite testing, some errors in our products may only be discovered after a product has been installed and used by customers. Any errors or defects discovered in our products after commercial release could result in failure to achieve market acceptance, loss of revenue or delay in revenue recognition, loss of customers and increased service and warranty cost, any of which could adversely affect our business, operating results and financial condition. In addition, we could face claims for product liability, tort or breach of warranty, including claims relating to changes to our products made by our channel partners. The performance of our products could have unforeseen or unknown adverse effects on the networks over which they are delivered as well as on third-party applications and services that utilize our services, which could result in legal claims against us, harming our business. Furthermore, we expect to provide implementation, consulting and other technical services in connection with the implementation and ongoing maintenance of our products, which typically involves working with sophisticated software, computing and communications systems. We expect that our contracts with customers will contain provisions relating to warranty disclaimers and liability limitations, which may not be upheld. Defending a lawsuit, regardless of its merit, is costly and may divert management’s attention and adversely affect the market’s perception of us and our products. In addition, if our business liability insurance coverage proves inadequate or future coverage is unavailable on acceptable terms or at all, our business, operating results and financial condition could be adversely impacted.

Index

Malfunctions of third-party communications infrastructure, hardware and software expose us to a variety of risks that we cannot control.

Our business will depend upon, among other things, the capacity, reliability and security of the infrastructure owned by third parties that we will use to deploy our offerings. We have no control over the operation, quality or maintenance of a significant portion of that infrastructure or whether or not those third parties will upgrade or improve their equipment. We depend on these companies to maintain the operational integrity of our connections. If one or more of these companies is unable or unwilling to supply or expand its levels of service to us in the future, our operations could be severely interrupted. Also, to the extent that the number of users of networks utilizing our current or future products suddenly increases, the technology platform and secure hosting services which will be required to accommodate a higher volume of traffic may result in slower response times or service interruptions. System interruptions or increases in response time could result in a loss of potential or existing users and, if sustained or repeated, could reduce the appeal of the networks to users. In addition, users depend on real-time communications; outages caused by increased traffic could result in delays and system failures. These types of occurrences could cause users to perceive that our solution does not function properly and could therefore adversely affect our ability to attract and retain licensees, strategic partners and customers.

System failure or interruption or our failure to meet increasing demands on our systems could harm our business.

The success of our license and service offerings will depend on the uninterrupted operation of various systems, secure data centers and other computer and communication networks that we establish. To the extent the number of users of networks utilizing our future products suddenly increases, the technology platform and hosting services which will be required to accommodate a higher volume of traffic may result in slower response times, service interruptions or delays or system failures. Our systems and operations will also be vulnerable to damage or interruption from, among other things:

•

power loss, transmission cable cuts and other telecommunications failures;

•

damage or interruption caused by fire, earthquake, and other natural disasters;

•

computer viruses or software defects; and

•

physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.

System interruptions or failures and increases or delays in response time could result in a loss of potential or existing users and, if sustained or repeated, could reduce the appeal of the networks to users. These types of occurrences could cause users to perceive that our solution does not function properly and could therefore adversely affect our ability to attract and retain licensees, strategic partners and customers.

Any significant problem with our systems or operations could result in lost revenue, customer dissatisfaction or lawsuits against us. A failure in the operation of our secure domain name registration system could result in the inability of one or more registrars to register and maintain secure domain names for a period of time. A failure in the operation or update of the master directory that we plan to maintain could result in deletion or discontinuation of assigned secure domain names for a period of time. The inability of the registrar systems we establish, including our back-office billing and collections infrastructure, and telecommunications systems to meet the demands of an increasing number of secure domain name requests could result in substantial degradation in our customer support service and our ability to process registration requests in a timely manner.

Our ability to sell our solutions will be dependent on the quality of our technical support, and our failure to deliver high-quality technical support services could have a material adverse effect on our sales and results of operations.

If we do not effectively assist our customers in deploying our products, succeed in helping our customers quickly resolve post-deployment issues and provide effective ongoing support, or if potential customers perceive that we may not be able achieve to the foregoing, our ability to sell our products would be adversely affected, and our reputation with current and potential customers could be harmed. In addition, as we expand our operations internationally, our technical support team will face additional challenges, including those associated with delivering support, training and documentation in languages other than English. Our failure to deliver and maintain high-quality technical support services to our customers could result in customers choosing to use our competitors’ products and support services instead of ours in the future.

Telephone carriers have petitioned governmental agencies to enforce regulatory tariffs, which, if granted, would increase the cost of online communication, and such increase in cost may impede the growth of online communication and adversely affect our business.

Use of the Internet has over-burdened existing telecommunications infrastructures, and many high traffic areas have begun to experience interruptions in service. As a result, certain local telephone carriers have petitioned governmental agencies to enforce regulatory tariffs on IP telephony traffic that crosses over their traditional telephone networks. If the relief sought in these petitions is granted, the costs of communicating via online could increase substantially, potentially adversely affecting the growth in the use of online secure communications. Any of these developments could have an adverse effect on our business.

Index

The departure of Kendall Larsen, our Chief Executive Officer and President, and/or other key personnel could compromise our ability to execute our strategic plan and may result in additional severance costs to us.

Our success largely depends on the skills, experience and efforts of our key personnel, including Kendall Larsen, our Chief Executive Officer and President. We have no employment agreements with any of our key executives that prevent them from leaving us at any time. In addition, we do not maintain key person life insurance for any of our officers or key employees. The loss of Mr. Larsen, or our failure to retain other key personnel, would jeopardize our ability to execute our strategic plan and materially harm our business.

We will need to recruit and retain additional qualified personnel to successfully grow our business.

Our future success will depend, in part, on our ability to attract and retain qualified engineering, operations, marketing, sales and executive personnel. Inability to attract and retain such personnel could adversely affect our business. Competition for engineering, operations, marketing, sales and executive personnel is intense, particularly in the technology and Internet sectors and in the regions where we conduct our business. We can provide no assurance that we will attract or retain such personnel.

We may identify future material weakness which may result in late filings, increased costs or declines in our share price.

Although we believe that we currently maintain effective control over our disclosures and procedures and internal control over financial reporting, we may in the future identify deficiencies regarding the design and effectiveness of our system of internal control over financial reporting. If we experience any material weaknesses in our internal control over financial reporting the future or are unable to provide unqualified management or attestation reports about our internal controls, we may be unable to meet financial and other reporting deadlines and may incur costs associated with remediation, and any of which could cause our share price to decline.

Risks Related to Our Common Stock

We do not currently pay dividends on our common stock and thus stockholders must look to appreciation of our common stock to realize a gain on their investments.

Our dividend policy is within the discretion of our Board of Directors and will depend upon various factors, including our business, financial condition, results of operations, capital requirements, and investment opportunities. We therefore cannot make assurances that our Board of Directors will determine to pay regular or special dividends in the future. Accordingly, unless our Board of Directors determines to pay dividends, stockholders will be required to look to appreciation of our common stock to realize a gain on their investment. This appreciation may not occur.

The exercise of our outstanding stock options and issuance of new shares would result in a dilution of our current stockholders’ voting power and an increase in the number of shares eligible for future resale in the public market which may negatively impact the market price of our stock.

The exercise of our outstanding vested stock options would dilute the ownership interests of our existing stockholders. As of March 31, 2017, we had outstanding options to purchase an aggregate of 5,403,571 shares of common stock representing 9.25% of our total shares outstanding of which 4,561,251 were vested and therefore exercisable. To the extent outstanding stock options are exercised, additional shares of common stock will be issued, existing stockholders’ percentage voting interests will decline and the number of shares eligible for resale in the public market will increase. Such increase may have a negative effect on the value or market trading price of our common stock.

Trading in our common stock is limited and the price of our common shares may be subject to substantial volatility.

Our common stock is listed on NYSE MKT. Over the past years the market price of our common stock has experienced significant fluctuations. Between April 1, 2016, and March 31, 2017, the reported last adjusted closing price on NYSE MKT for our common stock ranged between $1.85 and $6.20 per share. The price of our common stock may continue to be volatile as a result of a number of factors, some of which are beyond our control. These factors include, but not limited to, the following:

•

developments or lack thereof in any then-outstanding litigation;

•

quarterly variations in our operating results;

•

large purchases or sales of common stock or derivative transactions related to our stock;

•

actual or anticipated announcements of new products or services by us or competitors;

•

general conditions in the markets in which we compete; and

•

general social, political, economic and financial conditions, including the significant volatility in the global financial markets as a result of the announcement of the Referendum of the United Kingdom’s membership of the European Union, referred to as Brexit and concerns regarding the impact of the recent U.S. presidential election on domestic and international regulations, taxes of international trade agreements.

Index

In addition, we believe there has been and may continue to be substantial trading in derivatives of our stock, including short selling activity or related similar activities, which are beyond our control and which may be beyond the full control of the SEC and Financial Institutions Regulatory Authority or “FINRA”. While the SEC and FINRA rules prohibit some forms of short selling and other activities that may result in stock price manipulation, such activity may nonetheless occur without detection or enforcement. We have held conversations with regulators concerning trading activity in our stock; however, there can be no assurance that should there be any illegal manipulation in the trading of our stock, it will be detected, prosecuted or successfully eradicated. Significant short selling or other types of market manipulation could cause our stock trading price to decline, to become more volatile, or both.

The market price of our common stock may decline because our operating results may not be consistent and may be difficult to predict.

Our reported net income has fluctuated in the past due to several factors. We expect that our future operating results may also fluctuate due to the same or similar factors. We had a net loss of $29.2 million for the year ended December 31, 2015, a net loss of $28.6 million for the year ended December 31, 2016, and a net loss of $3.9 million for the quarter ended March 31, 2017, with an accumulated deficit of $162 million. The following include some of the factors that may cause our operating results to fluctuate:

•

the outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;

•

the amount and timing of receipt of license fees from potential infringers, licensees or customers;

•

the rate of adoption of our patented technologies;

•

the number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc.;

•

the success of a licensee in selling products that use our patented technologies; and

•

the amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.

These fluctuations may make our business particularly difficult to manage, adversely affect our business and operating results, make our operating results difficult for investors to predict and, further, cause our results to fall below investor’s expectations and adversely affect the market price of our common stock.

The market price of our common stock has been and may continue to be volatile, and you could lose all or part of your investment.

The trading price of our common stock has been volatile since our initial public offering, and is likely to continue to be volatile. Factors that could cause fluctuations in the market price of our common stock include, but are not limited to the following:

•

price and volume fluctuations in the overall stock market from time to time;

•

volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;

•

changes in operating performance and stock market valuations of other companies generally, or those in our industry;

•

sales of shares of our common stock by us or our stockholders;

•

failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;

•

the financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;

•

announcements by us or our competitors of new products or services;

•

the public’s reaction to our press releases, other public announcements and filings with the SEC;

•

rumors and market speculation involving us or other companies in our industry;

Index

•

actual or anticipated changes in our results of operations;

•

actual or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally;

•

litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

•

announced or completed acquisitions of businesses or technologies by us or our competitors;

•

new laws or regulations or new interpretations of existing laws or regulations applicable to our business;

•

changes in accounting standards, policies, guidelines, interpretations or principles;

•

any significant change in our management; and

•

general economic conditions and slow or negative growth of our markets.

Further, in recent years the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. In addition, the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, government shutdowns, interest rate changes the stability of the EU and the exit of the United Kingdom or international currency fluctuations, may cause the market price of our common stock to decline. In the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against these companies.

Because ownership of our common stock is concentrated, investors may have limited influence on stockholder decisions.

As of March 31, 2017, our executive officers and directors beneficially owned approximately 19% of our outstanding common stock. In addition, a group of stockholders that, as of December 31, 2007, held 4,766,666 shares, or approximately 8.4% of our then outstanding common stock, have entered into a voting agreement with us that requires them to vote all of their shares of our voting stock in favor of the director nominees approved by our Board of Directors at each director election going forward, and in a manner that is proportional to the votes cast by all other voting shares as to any other matters submitted to the stockholders for a vote. However, we cannot be certain how many shares of our common stock this group of stockholders currently owns. Because of their beneficial ownership interest, our officers and directors could significantly influence stockholder actions of which you disapprove or that are contrary to your interests. This ability to exercise significant influence could prevent or significantly delay another company from acquiring or merging with us.

Our protective provisions in our amended and restated certificate of incorporation and bylaws could make it difficult for a third party to successfully acquire us even if you would like to sell your stock to them.

We have a number of protective provisions in our amended and restated certificate of incorporation and bylaws that could delay, discourage or prevent a third party from acquiring control of us without the approval of our Board of Directors. These protective provisions include:

•

A staggered Board of Directors: This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.

•

Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the future, very rapidly and without stockholder approval.

•

Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.

•

No stockholder actions by written consent: No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.

Index

•

Super majority requirement for stockholder amendments to the By-laws: Stockholder proposals to alter or amend our By-laws or to adopt new By-laws can only be approved by the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.

•

No ability of stockholders to call a special meeting of the stockholders: Only the Board of Directors or management can call special meetings of the stockholders. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.

In addition, the provisions of Section 203 of the Delaware General Corporate Law govern us. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time.

These and other provisions in our amended and restated certificate of incorporation, our bylaws and under Delaware law could discourage potential takeover attempts, reduce the price that investors might be willing to pay for shares of our common stock in the future and result in the market price being lower than it would be without these provisions.

ITEM 5 — OTHER INFORMATION.

None

Index

ITEM 6 — EXHIBITS.

Exhibit Number	Description
31.1	Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data Files

This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference.

Index

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIRNETX HOLDING CORPORATION

By:	/s/ Kendall Larsen
	Name	Kendall Larsen

		Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Richard H. Nance
		Name	Richard H. Nance

			Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Date: May 8, 2017

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Kendall Larsen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of VirnetX Holding Corporation for the quarter ended March 31, 2017;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Kendall Larsen
	Kendall Larsen
	President and Chief Executive Officer
	(Principal Executive Officer)

Date: May 8, 2017

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Richard H. Nance, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of VirnetX Holding Corporation for the quarter ended March 31, 2017;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Richard H. Nance
	Richard H. Nance
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

Date: May 8, 2017

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of VirnetX Holding Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on May 8, 2017 (the “Report”), I, Kendall Larsen, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	/s/ Kendall Larsen
	Kendall Larsen
	President and Chief Executive Officer
	(Principal Executive Officer)

Date: May 8, 2017

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of VirnetX Holding Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on May 8, 2017 (the “Report”), I, Richard H. Nance, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	/s/ Richard H. Nance
	Richard H. Nance
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

Date: May 8, 2017

EX-101.INS 6 vhc-20170331.xml XBRL INSTANCE DOCUMENT 0001082324 2017-01-01 2017-03-31 0001082324 2017-05-05 0001082324 2016-12-31 0001082324 2017-03-31 0001082324 2016-01-01 2016-03-31 0001082324 2015-12-31 0001082324 2016-03-31 0001082324 country:US us-gaap:PatentsMember 2017-03-31 0001082324 us-gaap:NonUsMember us-gaap:PatentsMember 2017-03-31 0001082324 us-gaap:RoyaltyAgreementsMember 2017-01-01 2017-03-31 0001082324 us-gaap:RoyaltyAgreementsMember 2016-12-31 0001082324 us-gaap:RoyaltyAgreementsMember 2016-01-01 2016-03-31 0001082324 us-gaap:RoyaltyAgreementsMember 2017-03-31 0001082324 us-gaap:CashMember 2016-12-31 0001082324 us-gaap:CashMember 2017-03-31 0001082324 us-gaap:USGovernmentDebtSecuritiesMember 2016-12-31 0001082324 us-gaap:MutualFundMember 2017-03-31 0001082324 us-gaap:MutualFundMember 2016-12-31 0001082324 us-gaap:USTreasurySecuritiesMember 2017-03-31 0001082324 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001082324 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001082324 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001082324 us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001082324 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2017-03-31 0001082324 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001082324 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001082324 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001082324 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001082324 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001082324 us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001082324 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001082324 us-gaap:StateAndLocalJurisdictionMember 2017-03-31 0001082324 us-gaap:DomesticCountryMember 2017-03-31 0001082324 us-gaap:DomesticCountryMember 2017-01-01 2017-03-31 0001082324 us-gaap:StateAndLocalJurisdictionMember 2017-01-01 2017-03-31 0001082324 us-gaap:BuildingMember 2017-01-01 2017-03-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2017-01-01 2017-03-31 0001082324 vhc:K2InvestmentFundLLCMember us-gaap:AirTransportationEquipmentMember 2016-01-01 2016-03-31 0001082324 vhc:Plan2013Member 2017-03-31 0001082324 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001082324 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001082324 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001082324 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001082324 us-gaap:EmployeeStockOptionMember 2017-03-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2017-03-31 0001082324 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001082324 vhc:UniversalShelfRegistrationStatementMember 2015-08-21 0001082324 vhc:ATMAgreementMember 2015-08-20 0001082324 vhc:ATMAgreementMember us-gaap:CommonStockMember 2015-08-22 2017-03-31 0001082324 vhc:ATMAgreementMember us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001082324 vhc:ATMAgreementMember 2015-08-22 2017-03-31 0001082324 vhc:AdvisorWarrantsMember us-gaap:WarrantMember 2017-01-01 2017-03-31 0001082324 us-gaap:WarrantMember vhc:AdvisorWarrantsMember 2017-03-31 0001082324 us-gaap:WarrantMember 2016-12-31 0001082324 vhc:AdvisorWarrantsMember us-gaap:WarrantMember 2016-12-31 0001082324 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001082324 us-gaap:WarrantMember 2017-03-31 0001082324 us-gaap:PositiveOutcomeOfLitigationMember 2017-03-31 0001082324 vhc:VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember us-gaap:PositiveOutcomeOfLitigationMember 2015-03-30 2015-03-30 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember 2015-03-30 2015-03-30 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVAppleIncCase612CV00855LEDMember 2015-03-30 2015-03-30 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember 2016-09-30 2016-09-30 0001082324 vhc:VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember us-gaap:PositiveOutcomeOfLitigationMember 2012-11-06 2012-11-06 0001082324 vhc:VirnetXIncVAppleIncCase612CV00855LEDMember us-gaap:PositiveOutcomeOfLitigationMember 2016-02-04 2016-02-04 0001082324 vhc:VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember us-gaap:PositiveOutcomeOfLitigationMember 2012-11-06 2012-11-06 0001082324 vhc:VirnetXIncVAppleIncCase612CV00855LEDAppleIIMember us-gaap:PositiveOutcomeOfLitigationMember 2016-07-29 2016-07-29 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVAppleIncCase612CV00855LEDMember 2016-07-29 2016-07-29 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember 2016-07-29 2016-07-29 0001082324 us-gaap:PositiveOutcomeOfLitigationMember vhc:VirnetXIncVCiscoSystemsIncEtAlCase610CV00417LEDAppleIMember 2013-02-26 2013-02-26 xbrli:shares iso4217:USD iso4217:USD xbrli:shares vhc:Patent vhc:Institution xbrli:pure vhc:Lawsuit vhc:Action vhc:Case false --12-31 2017-03-31 No No Yes Accelerated Filer VirnetX Holding Corp 0001082324 58144888 2017 Q1 10-Q

1806000

651000

396000

401000

-12000

-17000

170224000

169391000

132000

252000

1234000

833000

1234000

833000

12909000

18871000

16464000

10606000

7995000

1662000

3195000

1254000

6129000

12444000

7791000

7995000

9249000

1254000

6129000

9249000

6129000

2000

3000

4000

3000

7795000

1254000

1662000

3195000

6133000

12445000

7996000

9249000

6129000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Note 2 —  Summary of Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Unaudited Interim Financial Information</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The accompanying Condensed Consolidated Balance Sheet as of March 31, 2017, the Condensed Consolidated Statements of Income for the three months ended March 31, 2017 and 2016, the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016, and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2017, our results of operations for the three months ended March 31, 2017 and 2016, and our cash flows for the three months ended March 31, 2017 and 2016. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 16, 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Use of Estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We prepare our consolidated financial statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in our accounting estimates are reasonably likely to occur. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, at the time they are made and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Basis of Consolidation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: left;">Revenue Recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We derive our revenue from patent licensing. The timing and amount of revenue recognized from each licensee depends upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Such agreements may be complex and include multiple elements. These agreements may include, without limitation, elements related to the settlement of past patent infringement liabilities, up-front and non-refundable license fees for the use of patents, patent licensing royalties on covered products sold by licensees, and the compensation structure and ownership of intellectual property rights associated with contractual technology development arrangements. Licensing agreements are accounted for under the Financial Accounting Standards Board (“FASB”) revenue recognition guidance, “Revenue Arrangements with Multiple Deliverables.” This guidance requires consideration to be allocated to each element of an agreement that has stand-alone value using the relative fair value method. In other circumstances, such as those agreements involving consideration for past and expected future patent royalty obligations, after consideration of the particular facts and circumstances, the appropriate recording of revenue between periods may require the use of judgment. In all cases, revenue is only recognized after all the following criteria are met: (1) written agreements have been executed; (2) delivery of technology or intellectual property rights has occurred or services have been rendered; (3) fees are fixed or determinable; and (4) collectability of fees is reasonably assured.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Patent License Agreements</font>: Upon signing a patent license agreement, including licenses entered upon settlement of litigation, we provide the licensee permission to use our patented technology in specific applications. We account for patent license agreements in accordance with the guidance for revenue recognition for arrangements with multiple deliverables, with amounts allocated to each element based on their fair values. We have elected to utilize the leased-based model for revenue recognition with revenue being recognized over the expected period of benefit to the licensee. Under our patent license agreements, we do or expect to typically receive one or a combination of the following forms of payment as consideration for permitting our licensees to use our patented inventions in specific applications and products:</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">•<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Consideration for Past Sales</font>: Consideration related to a licensee’s product sales from prior periods may result from a negotiated agreement with a licensee that utilized our patented technology prior to signing a patent license agreement with us or from the resolution of a litigation, disagreement or arbitration with a licensee over the specific terms of an existing license agreement. We may also receive royalty for past sales in connection with the settlement of patent litigation where there was no prior patent license agreement. These amounts are negotiated, typically based upon application of a royalty rate to historical sales prior to the execution of the license agreement. In each of these cases, because delivery has occurred, we record the consideration as revenue when we have obtained a signed agreement, identified a fixed or determinable price, and determined that collectability is reasonably assured.</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">• <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Current Royalty Payments</font>: Ongoing royalty payments cover a licensee’s obligations to us related to its sales of covered products in the current contractual reporting period. Licensees that owe these current royalty payments are obligated to provide us with quarterly or semi-annual royalty reports that summarize their sales of covered products and their related royalty obligations to us. We expect to receive these royalty reports subsequent to the period in which our licensees’ underlying sales occurred. As a result, it is impractical for us to recognize revenue in the period in which the underlying sales occur, and, in most cases, we will recognize revenue in the period in which the royalty report is received and other revenue recognition criteria are met due to the fact that without royalty reports from our licensees, our visibility into our licensees’ sales is limited.</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">• <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Non-Refundable Up-Front Fees and Minimum Fee Contracts</font>: For licenses that provide for non-refundable up-front or fixed minimum fees over their term, for which we have no future obligations or performance requirements, revenue is generally recognized over the license term. For licenses that provide for fees that are not fixed or determinable, including licenses that provide for extended payment terms and/or payment of a significant portion of the fee after expiration of the license or more than 12 months after delivery, the fees are generally presumed not to be fixed or determinable, and revenue is deferred and recognized as earned, but generally not in advance of collection.</div><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">• <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Non-Royalty Elements</font>: Elements that are not related to royalty revenue in nature, such as settlement fees, expense reimbursement, and damages, if any, are recorded as gain from settlement which is reflected as a separate line item within the operating expenses section in the consolidated statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Deferred revenue</div><div><br /></div><div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In August 2013, we began receiving annual payments on a contract requiring payment to us over 4 years totaling $10,000 ("August 2013 Contract Settlement"). In accordance with our revenue recognition policy we defer and recognize revenue over the life of the contract, but not ahead of collection. We collected the final payment under the contract in 2016 and recognized $375 of revenue, related to the August 2013 Contract Settlement, during the three months ended March 31, 2017 and 2016.</div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Activity under the August 2013 Contract Settlement was as follows:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 68%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Deferred Revenue, December 31, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 68%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Less: Amount amortized as revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 68%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Deferred Revenue, March 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,625</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table><div style="text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Earnings Per Share</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period.  Diluted earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Concentration of Credit Risk and Other Risks and Uncertainties</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our cash and cash equivalents are primarily maintained at two major financial institutions in the United States. A portion of those balances are insured by the Federal Deposit Insurance Corporation.  During the three months ended March 31, 2017 we had funds which were uninsured.   We do not believe that we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships with major financial institutions. We have not experienced any losses on our deposits of cash and cash equivalents.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: left;">Prepaid Expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Prepaid expenses at March 31, 2017 include the current portion of prepaid rent for a facility lease for corporate promotional and marketing purposes. From inception, the prepayment totaling $4,000 is being amortized over the 10-year term of the lease. The unamortized non-current portion of the prepayment is included in Prepaid expenses-non-current on the consolidated balance sheet.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: left;">Impairment of Long-Lived Assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On an annual basis, we identify and record impairment losses on long-lived assets when events and changes in circumstances indicate that the carrying amount of an asset might not be recoverable.  Recoverability is measured by comparison of the anticipated future net undiscounted cash flows to the related assets’ carrying value.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Fair Value of Financial Instruments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).  Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our financial instruments are stated at amounts that equal, or approximate, fair value.  When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique.  We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mutual Funds:</font> Valued at the quoted net asset value of shares held.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">U.S. government and U.S. agency securities</font>:  Fair value measured at the closing price reported on the active market on which the individual securities are traded.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following tables show the adjusted cost, gross unrealized gains, gross unrealized losses and fair value of our securities by significant investment category as of March 31, 2017 and December 31, 2016.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available for</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,795</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,791</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,742</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,738</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,609</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">December 31, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Fair</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Available</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">for Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. government securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,996</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,445</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,444</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,877</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,876</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,627</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">New Accounting Pronouncements</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326). The purpose of this ASU is to require a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. We are evaluating the impact this guidance will have on our financial position and statement of operations.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. ASU 2016-09 will be effective for us beginning the first quarter of 2018. We are evaluating the impact of adopting the new stock compensation standard on our consolidated financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. We are evaluating the impact this guidance will have on our financial position and statement of operations.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In November 2015, the FASB issued ASU <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><font style="font-style: normal;">No. 2015-17—Income Taxes (Topic 740)</font>.</font> Current GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, this Update requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. For public business entities, the amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. We adopted this update in 2017 and implementation did not have a material impact on our financial position or statement of operations.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In May 2014, the FASB issued ASU No. 2014-09 <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal;">Revenue from Contracts with Customers</font> (Topic 606). This ASU was subsequently amended by ASU No. 2016-10 and 2016-12. As amended, Topic 606 supersedes the revenue recognition requirements in Topic 605,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: normal;">Revenue Recognition</font><font style="font-style: normal;"> including </font>most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments create a new Subtopic 340-40,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><font style="font-style: normal;">Other Assets and Deferred Costs—Contracts with Customers</font>.</font>  In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For a public entity, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are currently evaluating the impact this guidance will have on our financial position and statement of operations.</div></div>

6627000

3609000

8726000

9269000

3432000

1947000

3432000

3195000

1662000

3432000

6627000

1662000

1947000

3609000

25000

7.00

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Note 4 — Commitments And Related Party Transactions</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We lease our offices under an operating lease with a third party expiring in October 2017. We recognize rent expense on a straight-line basis over the term of the lease.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We lease the use of an aircraft from K2 Investment Fund LLC (‘‘LLC’’) for business travel for employees of the Company. We incurred approximately $252 and $132 in rental fees and reimbursements to LLC during the three months ended March 31, 2017 and 2016, respectively. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of LLC. On January 31, 2015, we entered into a 12-month non-exclusive lease with LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or LLC with 30 days’ notice. The lease renews on an annual basis unless terminated by the lessor or lessee. Neither party has exercised their termination rights.</div></div>

58144888

100000000

6000

0.0001

58144888

-3899000

-8601000

375000

1500000

4000000

3625000

2500000

2125000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Activity under the August 2013 Contract Settlement was as follows:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 68%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Deferred Revenue, December 31, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 68%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Less: Amount amortized as revenue</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 68%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Deferred Revenue, March 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,625</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table></div>

46000000

44000000

6000

9000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Note 5 — Stock Based Compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We have a stock incentive plan for employees and others called the “VirnetX Holding Corporation 2013 Equity Incentive Plan”, or the Plan, which has been approved by our stockholders. The Plan provides for the granting of up to 14,124,469 shares of our common stock, including stock options and stock purchase rights (“RSUs”), and will expire in 2024. As of March 31, 2017, 396,221 shares remained available for grant under the Plan. During the three months ending March 31, 2017 we granted options for a total of 25,000 shares with a weighted average grant date fair value of $1.69. During the three months ended March 31, 2016 there were no grants of options or RSUs.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Stock-based compensation expense included in general and administrative expense was $833 and $1,234 for the three months ended March 31, 2017 and 2016, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of March 31, 2017, the unrecognized stock-based compensation expense related to non-vested stock options and RSUs was $3,339 and $2,137, respectively, which will be amortized over an estimated weighted average period of approximately 2.54 and 2.20 years, respectively.</div></div>

-0.07

-0.16

150000

1522000

P2Y6M14D

P2Y2M12D

2137000

3339000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Fair Value of Financial Instruments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Fair value is the price that would result from an orderly transaction between market participants at the measurement date. A fair value hierarchy prioritizes the inputs used to measure fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).  Level 2 measurements utilize either directly or indirectly observable inputs in markets other than quoted prices in active markets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our financial instruments are stated at amounts that equal, or approximate, fair value.  When we estimate fair value, we utilize market data or assumptions that we believe market participants would use in pricing the financial instrument, including assumptions about risk and inputs to the valuation technique.  We use valuation techniques, primarily the income and market approach, which maximizes the use of observable inputs and minimize the use of unobservable inputs for recurring fair value measurements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mutual Funds:</font> Valued at the quoted net asset value of shares held.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">U.S. government and U.S. agency securities</font>:  Fair value measured at the closing price reported on the active market on which the individual securities are traded.</div><div style="text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following tables show the adjusted cost, gross unrealized gains, gross unrealized losses and fair value of our securities by significant investment category as of March 31, 2017 and December 31, 2016.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available for</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,795</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,791</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,742</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,738</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,609</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">December 31, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Fair</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Available</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">for Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. government securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,996</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,445</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,444</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,877</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,876</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,627</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The following tables show the adjusted cost, gross unrealized gains, gross unrealized losses and fair value of our securities by significant investment category as of March 31, 2017 and December 31, 2016.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cash and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available for</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,947</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,133</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,795</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,791</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,662</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,742</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,738</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,609</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,129</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">December 31, 2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Adjusted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cost</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Gains</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Unrealized</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Losses</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Fair</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Value</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">and Cash</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Equivalents</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Investments</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">Available</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; text-indent: 2pt;">for Sale</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,432</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Level 1:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Mutual funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. government securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,254</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">U.S. agency securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,996</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,995</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,445</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">12,444</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 28%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,877</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">15,876</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,627</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">9,249</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

-8603000

-3889000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Note 3 — Income Taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We had income tax expense of $5 and $7 for the three months ended March 31, 2017 and 2016, respectively, as a result of minimum tax payments.  During the three month period ended March 31, 2017, we had net operating losses (“NOLs”) which generated deferred tax assets for NOL carry-forwards.  We provided valuation allowances against the net deferred tax assets including the deferred tax assets for NOL carryforwards.  Valuation allowances provided for our net deferred tax assets increased by approximately $1,786 and $3,342 for the three months ended March 31, 2017 and 2016, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets at March 31, 2017 will not be fully realizable. Accordingly, management has maintained a full valuation allowance against its net deferred tax assets at March 31, 2017. The valuation allowance carried against our net deferred tax assets was approximately $46,000 and $44,000 at March 31, 2017 and December 31, 2016, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">At March 31, 2017, we have federal and state net operating loss carry-forwards of approximately $78,000 and $61,000, respectively, expiring beginning in 2027 and began in 2016 for state, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to net operating losses and tax credits remaining unutilized from such years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our policy is to recognize interest and penalties accrued on uncertain tax positions as a component of income tax expense. As of March 31, 2017, we had accrued immaterial amounts of interest and penalties related to the uncertain tax positions.</div></div>

5000

7000

5000

-1155000

1643000

-375000

-11000

-1372000

-1383000

185000

108000

17000

15000

P10Y

P12M

2017-10-31

2015-01-31

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Note 7 — Litigation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">We have nine intellectual property infringement lawsuits pending in the United States District Court for the Eastern District of Texas, Tyler Division, and United States Court of Appeals for the Federal Circuit (“USCAFC”).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 30, 2015, the United States Court for the Eastern District of Texas, Tyler Division, issued an order finding substantial overlap between the remanded portions of the Civil Action Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.), and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. The jury trial in this case was held on January 25, 2016. On February 4, 2016, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us $625.6 million in a verdict against Apple Inc. for infringing four of our US patents, marking it the second time a federal jury has found Apple liable for infringing VirnetX’s patented technology. The verdict includes royalties awarded to us based on an earlier patent infringement finding<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (Case 6:10-CV-00417-LED)</font> against Apple. The jury found that Apple’s modified VPN On-Demand, iMessage and FaceTime services infringed VirnetX’s patents and that Apple’s infringement was willful. In addition to determining the royalty owed by Apple for its prior infringement, this verdict also includes an award based on the jury’s finding that Apple’s modified VPN On Demand, iMessage and FaceTime services have continued to infringe VirnetX’s patents. The post-trial hearing was held on May 25, 2016 in the United States Court for the Eastern District of Texas, Texarkana Division. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases (Case No. 6:10-cv-417, Docket No. 878 (“Apple I case”); Case No. 6:12-cv-855, Docket No. 220 (“Apple II case”)), ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II case will be retried after Apple I case. Events and developments subsequent to the order from the court are described to support Apple I and Apple II matters.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (“Apple I”)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On August 11, 2010, we initiated a lawsuit by filing a complaint against Aastra USA. Inc. (“Aastra”), Apple, Cisco Systems, Inc. (“Cisco”), and NEC Corporation (“NEC”) in the United States District Court for the Eastern District of Texas, Tyler Division, pursuant to which we alleged that these parties infringe on certain of our patents. We sought damages and injunctive relief. Aastra and NEC agreed to sign license agreements with us and we agreed to drop all the accusations of infringement against them. At the pre-trial hearing, the judge decided to conduct separate jury trial for each defendant, and try only the case against Apple on the scheduled trial date. The jury trial of our case against Cisco was held on March 4, 2013. The jury in our case against Cisco came back with a verdict of non-infringement also determined that all our patents-in-suit patents are not invalid. Our motions for a new trial and Cisco’s infringement of certain VirnetX patents were denied and the case against Cisco was closed.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The jury trial of our case against Apple was held on October 31, 2012. On November 6, 2012, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us over $368 million in a verdict against Apple for infringing four of our patents. On February 26, 2013, the court issued its Memorandum Opinion and Order regarding post-trial motions resulting from the prior jury verdict denying Apple’s motion to reduce the damages awarded by the jury for past infringement. The Court further denied Apple’s request for a new trial on the liability and damages portions of the verdict and granted our motions for pre-judgment interest, post-judgment interest, and post-verdict damages to date. The Court ordered that Apple pay $34 thousand in daily interest up to final judgment and $330 thousand in daily damages for infringement up to final judgment for certain Apple devices included in the verdict. The Court denied our request for a permanent injunction and severed the future infringement portion into its own separate proceedings under Case 6:13-CV-00211-LED.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On July 3, 2013, Apple filed an appeal of the judgment dated February 27, 2013 and order dated June 4, 2013 denying Apple’s motion to alter or amend the judgment to the USCAFC. On September 16, 2014, USCAFC issued their opinion, affirming the jury’s finding that all 4 of our patents are valid, confirming the jury’s finding of infringement of VPN on Demand under many of the asserted claims of our ‘135 and ‘151 patents, and confirming the district’s court’s decision to allow evidence concerning our licenses and royalty rates in connection with the determination of damages. In its opinion, the USCAFC also vacated the jury’s damages award and the district court’s claim construction with respect to parts of our ‘504 and ‘211 patents and remanded the damages award and determination of infringement with respect to FaceTime –for further proceedings consistent with its opinion. On October 16, 2014, we filed a petition with the USCAFC, requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision concerning VirnetX’s litigation against Apple Inc. On December 16, 2014, USCAFC denied our petition requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision and remanded the case back to the Eastern District of Texas, Tyler Division, for further proceedings consistent with its opinion. On February 25, 2015, USCAFC granted Apple’s motions to lift stay of proceedings and vacate Case 6:13-CV-00211-LED. On March 30, 2015, the court issued an order finding substantial overlap between the remanded portions of this case and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case.  The jury trial in this case was held on September 26, 2016. On September 30, 2016, a Jury in the United States Court for the Eastern District of Texas, Tyler Division, in the case VirnetX Inc., et al. v. Apple Inc., No. Apple I, has awarded VirnetX $302.4 million in a verdict against Apple for infringing four VirnetX patents, marking the third time a federal jury has found Apple liable for infringing VirnetX’s patented technology.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The verdict includes royalties awarded to VirnetX, for unresolved issues in the Apple I case, remanded back from the USCAFC, related to (1) damages owed to VirnetX for infringement by Apple’s original VPN-on-Demand (VOD) and (2) the alleged infringement by Apple’s original FaceTime product, under the new claim construction of “secure communication link” pertaining to the ’504 and ’211 patents by the USCAFC, and the damages associated with that infringement. The hearing on all the post-trial motions was held on November 22, 2016. We are currently awaiting the court ruling and final judgement in this case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On November 6, 2012, we filed a new complaint against Apple in the United States District Court for the Eastern District of Texas, Tyler Division for willfully infringing four of our patents, U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151, and seeking both an unspecified amount of damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Due to their release dates, these products were not included in the previous lawsuit that concluded with a Jury verdict on November 6, 2012 that was subsequently upheld by the United States District Court for the Eastern District of Texas, Tyler Division, on February 26, 2013. On July 1, 2013, we filed a consolidated and amended complaint to include U.S. Patent No. 8,051,181 and consolidate Civil Action No. 6:11-cv-00563-LED. On August 27, 2013, we filed an amended complaint including allegations of willful infringement related to U.S. Patent No. 8,504,697 seeking both damages and injunctive relief. The Markman hearing in this case was held on May 20, 2014 and on August 8, 2014, issued its Markman Order, denying Apple’s motion for summary judgment of indefiniteness, in which Apple alleged that some of the disputed claims terms in the patents asserted by us were invalid for indefiniteness. In a separate order, the court granted in part and denied in part our motion for partial summary judgment on Apple’s invalidity counterclaims, precluding Apple from asserting invalidity as a defense against infringement of the claims that were tried before a jury in our prior litigation against Apple (VirnetX vs. Cisco et. al., Case 6:10-CV-00417-LED). The jury trial in this case was scheduled for October 13, 2015. On March 30, 2015, the court issued an order finding substantial overlap between this case and the remanded portions of Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case. We are awaiting court order setting the date for a new jury trial in Apple II case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 15-1934)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On July 10, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the United States Patent and Trademark Office, Patent Trial and Appeal Board (“PTAB”) in IPR2014-00237 and IPR2014-00238, related to U.S. Patent No. 8,504,697. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00238. We are currently evaluating our options in this case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 16-1211)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On September 28, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2014-00403 and IPR2014-00404 and on October 22, 2015 for IPR2014-00481 and IPR2014-00482 involving our U.S. Patent Nos. 7,188,180, and 7,987,274. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00403 and IPR2014-00481. We are currently evaluating our options in this case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 16-1480)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On November 30, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in inter-partes reexamination no. 95/001,949 related to U.S. Patent No. 8,051,181. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on certain grounds. We are currently evaluating our options in this case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (case 16-119)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 4, 2016, we filed a petition for writ of mandamus with the USCAFC, requesting the USCAFC’s intervention to revoke the PTAB’s decision joining Apple to IPR2015-01046 and IPR2015-01047, related to U.S. Patent Nos. 6,502,135 and 7,490,151. On March 18, 2016, the USCAFC denied the petition without prejudice to us raising the arguments on appeal after the PTAB’s final decisions. We are currently evaluating our options in this case.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. Apple, Inc. (Case 17-1131)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On October 31, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-00810, IPR2015-00812, on November 9, 2016 for IPR2015-00811, and on November 28, 2016 for IPR2015-00866, IPR2015-00868, IPR2015-00870, IPR2015-00871 involving our U.S. Patent Nos.8,868,705, 8,850,009, 8,458,341, 8,516,131, and 8,560,705. These appeals have been consolidated.</div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">VirnetX Inc. v. The Mangrove Partners (Case 17-1368)</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On December 16, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-01046, and on December 20, 2016 for IPR2015-1047, involving our U.S. Patent Nos. 6,502,135, and 7,490,151. These appeals also involve Apple, Inc. and one of them involves Black Swamp IP, LLC.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are worth pursuing, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we will prevail on such potential claims. In addition, bringing a lawsuit may lead to potential counterclaims which may preclude our ability to commercialize our initial products, which are currently in development. Currently, we are not a party to any other pending legal proceedings, and are not aware of any proceeding threatened or contemplated against us by any governmental authority or other party.</div></div>

4827000

7724000

18871000

12909000

5224000

2702000

302400000

368000000

625600000

1362000

3116000

6815000

-7634000

-6134000

543000

-3018000

-3894000

-8610000

8993000

4281000

61000000

78000000

-8618000

-3906000

2027-12-31

2016-12-31

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Note 1 — Business Description and Basis of Presentation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to license our technology, including GABRIEL Connection Technology™, to various original equipment manufacturers, or OEMs, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence and unified communications markets. Prior to 2012 our revenue was limited to an insignificant amount of software royalties pursuant to the terms of a single license agreement. Since 2012 we had revenues from settlements of patent infringement disputes whereby we received consideration for past sales of licensees that utilized our technology, where there was no prior patent license agreement, as well as license agreement revenues from settlements providing licensing for the continued use of our technology (see “Revenue Recognition”).</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 49 U.S. and 69 foreign patents with approximately 50 pending patent applications worldwide. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security for Cloud services, Machine-to-Machine (“M2M”), communications in areas including “Smart City,” “Connected Car” and “Connected Home.” All our U.S. and foreign patents and pending patent applications relate generally to securing communications over the internet and as such, cover all our technology and other products. Our issued U.S. and foreign patents expire at various times during the period from 2019 to 2024. Some of our issued patents and pending patent applications were acquired by our principal operating subsidiary, VirnetX, Inc., from Leidos, Inc. (“Leidos”) (f/k/a Science Applications International Corporation, or SAIC) in 2006 and we are required to make payments to Leidos based on cash or certain other values generated from those patents in certain circumstances. The amount of such payments depends upon the type of value generated and certain categories are subject to maximums and other limitations.</div></div>

-4000

9000

-1000

-5000

9000

2752000

2000

10000000

0.0001

588000

868000

4000000

2279000

2374000

6795000

4116000

3116000

20000

33000

24000

450000

475000

-162131000

-158238000

375000

P5Y

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Information about warrants outstanding during the three months ended March 31, 2017 follows:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Original</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Warrants</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Issued</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price per</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Common</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable at</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Became</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercised</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Terminated /</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cancelled /</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Expired</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">at March 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Expiration</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">April 2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td></tr></table></div>

8543000

3806000

25000

14124469

0.0133

396221

0.875

1.69

5595650

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Note 6 — Equity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Common Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On August 21, 2015, we filed a Universal Shelf Registration Statement with the SEC enabling us to offer and sell from time to time up to $100 million of equity, debt or other types of securities.  We also entered into an at-the-market (“ATM”) equity offering sales agreement with Cowen & Company, LLC on August 20, 2015, under which we may offer and sell shares of our common stock having an aggregate value of up to $35 million. We have and expect to use proceeds from this offering for GABRIEL product development and marketing, and general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses. From August 20, 2015 through March 31, 2017, we sold 5,595,650 shares under the ATM. The average sales price per common share was $4.14 and the aggregate proceeds from the sales totaled $23,169 during the period. Sales commissions, fees and other costs associated with the ATM totaled $695.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">During the three months ended March 31, 2017, there were no shares sold under the ATM.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Warrants</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In 2015 we issued warrants (“Advisor Warrants”) for the purchase of 25,000 shares of common stock at an exercise price of $7 per share, which expire in April 2020.  The Advisor Warrants were issued for advisory services provided by a third party. Our Advisor Warrants were recorded at fair value on the issuance date and included in Additional Paid in Capital on our Condensed Consolidated Balance Sheet.  The Advisor Warrants are exercisable by the holder, in whole or in part, until expiration, and may also be net-share-settled. Terms of the warrant agreement include no registration requirements for the underlying common stock and there are no anti-dilution provisions.  The fair value at issuance of the warrants was recorded in Prepaid Expenses and Other Current Assets, and was amortized over the twelve-month life of the service contract, with the expense included in Selling, General and Administrative Expense in our Condensed Consolidated Statements of Operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The fair value of the Advisor Warrants at the issuance date of $121 was estimated utilizing the Black-Scholes valuation model with the following assumptions: (i) dividend yield on our common stock of 0 percent, (ii) expected stock price volatility of 87.5 percent, (iii) a risk-free interest rate of 1.33 percent, and (iv) an expected warrant term of 5 years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Information about warrants outstanding during the three months ended March 31, 2017 follows:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Original</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Warrants</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Issued</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Price per</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Common</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Share</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable at</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Became</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercised</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Terminated /</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Cancelled /</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Expired</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercisable</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">at March 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Expiration</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Date</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"> </td></tr><tr><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 2px; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">April 2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">—</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">25,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 10%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td></tr></table></div>

8082000

11147000

3342000

1786000

58145000

54135000

34000 330000 2 2 2 2 2 2 P30D 8000 4.14 100000000 35000000 23169000 695000 P12M 15876000 9738000 9742000 15877000 2 P4Y 10000000 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: left;">Prepaid Expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Prepaid expenses at March 31, 2017 include the current portion of prepaid rent for a facility lease for corporate promotional and marketing purposes. From inception, the prepayment totaling $4,000 is being amortized over the 10-year term of the lease. The unamortized non-current portion of the prepayment is included in Prepaid expenses-non-current on the consolidated balance sheet.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic; text-align: justify;">Unaudited Interim Financial Information</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The accompanying Condensed Consolidated Balance Sheet as of March 31, 2017, the Condensed Consolidated Statements of Income for the three months ended March 31, 2017 and 2016, the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2017 and 2016, and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of March 31, 2017, our results of operations for the three months ended March 31, 2017 and 2016, and our cash flows for the three months ended March 31, 2017 and 2016. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 16, 2017.</div></div> 49 69 50 April 30, 2020 121000 P12M 0 -30000

EX-101.SCH 7 vhc-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Business Description and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Commitments And Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Business Description and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Commitments And Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Equity, Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 090602 - Disclosure - Equity, Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vhc-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 vhc-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 vhc-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] Summary of Significant Accounting Policies [Abstract] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Income tax liability Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Adjustments to reconcile net loss to net cash used in operating activities: Aircraft [Member] Air Transportation Equipment [Member] Rental fees incurred for use of aircraft Stock-based compensation Stock-based compensation expense Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract] Assets, Fair Value Disclosure [Abstract] Total assets Assets ASSETS Assets [Abstract] Current assets: Total current assets Assets, Current Investments Available for Sale Fair Value Available-for-sale Securities Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Investments available for sale Available-for-sale Securities, Debt Securities, Current Summary of Significant Accounting Policies Offices [Member] Building [Member] Counterparty Name [Axis] Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Adjusted Cost Cash [Member] Fair Value Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Original number of warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Line Items] Exercise price per common share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Domain] Commitments and contingencies (Note 4) Commitments And Related Party Transactions Commitments Disclosure [Text Block] Commitments And Related Party Transactions [Abstract] Common Stock [Member] Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at March 31, 2017 and December 31, 2016, Issued and outstanding: 58,144,888 shares and 58,144,888 shares, at March 31, 2017 and December 31, 2016, respectively Common stock, par value (in dollars per share) Common stock, shares outstanding (in shares) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration of Credit Risk and Other Risks and Uncertainties Basis of Consolidation Less: Amount amortized as revenue Deferred revenue, current portion Deferred Revenue, Current Deferred Revenue [Abstract] Deferred Revenue, beginning of period Deferred Revenue, end of period Deferred Revenue Deferred Revenue [Domain] Deferred revenue, non-current portion Deferred Revenue, Noncurrent Schedule of Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement, by Type [Table] Valuation allowance carried against net deferred tax assets Deferred Tax Assets, Valuation Allowance Depreciation Stock Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Based Compensation [Abstract] Federal [Member] Basic and diluted loss per share (in dollars per share) Earnings Per Share, Basic and Diluted Earnings Per Share Accrued payroll and related expenses Weighted average amortization period Unrecognized stock-based compensation expense expected to be recognized related to non-vested RSUs Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Stock Options [Member] Unrecognized stock-based compensation expense expected to be recognized related to non-vested stock options Equity [Abstract] Equity Component [Domain] Asset Class [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Asset Class [Domain] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Measurement Frequency [Domain] Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Hierarchy [Domain] Fair Value of Financial Instruments Cash and Available-for-Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value by Significant Investment Category Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of patents allegedly infringed upon by Apple, Inc. Gain Contingency, Patents Found Infringed upon, Number Gain Contingencies [Line Items] Gain Contingencies [Table] Gain Contingency, Nature [Domain] Gain Contingencies, Nature [Axis] General and Administrative Expense [Member] Geographic Distribution [Axis] Geographic Distribution [Domain] Intellectual Property [Member] Impairment of Long-Lived Assets Income Taxes [Abstract] Income Statement Location [Axis] Loss before taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income Statement Location [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Taxes Income Tax Disclosure [Text Block] Income tax expense Provision for income taxes Income Tax Expense (Benefit) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] Cash paid for income taxes Income tax liability Increase (Decrease) in Income Taxes Payable Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Related party payable Accrued payroll and related expenses Increase (Decrease) in Employee Related Liabilities Changes in assets and liabilities: Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Interest income, net Lease term Term of lease Lessee Leasing Arrangements, Operating Leases, Term of Contract Operating lease expiration date Litigation Legal Matters and Contingencies [Text Block] Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Total current liabilities Liabilities, Current Current liabilities: Litigation Case [Domain] Litigation Case [Axis] Amount of damages awarded in patent infringement case Loss Contingency, Damages Awarded, Value Number of intellectual property infringement lawsuits pending Loss Contingency, Pending Claims, Number Mutual Funds [Member] Mutual Fund [Member] Activity under August 2013 contract settlement [Roll Forward] Cash flows from financing activities: Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows from operating activities: Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash flows from investing activities: Net increase (decrease) in cash and cash equivalents Net Cash Provided by (Used in) Continuing Operations Net loss Net loss Net Income (Loss) Attributable to Parent New Accounting Pronouncements Foreign [Member] Non-US [Member] Operating expense: Total operating expense Operating Expenses Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards Loss from operations Operating Income (Loss) Operating loss carryforwards, expiration dates Operating Leased Assets [Line Items] Business Description and Basis of Presentation [Abstract] Business Description and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Change in unrealized gain (loss) on investments, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax EX-101.PRE 11 vhc-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 image0.jpg begin 644 image0.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2017

May 05, 2017

Document and Entity Information [Abstract]

Entity Registrant Name VirnetX Holding Corp

Entity Central Index Key 0001082324

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 58,144,888

Document Fiscal Year Focus 2017

Document Fiscal Period Focus Q1

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2017

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,609	$ 6,627
Investments available for sale	6,129	9,249
Prepaid expenses and other current assets	868	588
Total current assets	10,606	16,464
Prepaid expenses, non-current	2,279	2,374
Property and equipment, net	24	33
Total assets	12,909	18,871
Current liabilities:
Accounts payable and accrued liabilities	651	1,806
Accrued payroll and related expenses	150	1,522
Income tax liability	401	396
Deferred revenue, current portion	1,500	1,500
Total current liabilities	2,702	5,224
Deferred revenue, non-current portion	2,125	2,500
Total liabilities	4,827	7,724
Commitments and contingencies (Note 4)
Stockholders' equity:
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at March 31, 2017 and December 31, 2016, Issued and outstanding: 0 shares at March 31, 2017 and December 31, 2016	0	0
Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at March 31, 2017 and December 31, 2016, Issued and outstanding: 58,144,888 shares and 58,144,888 shares, at March 31, 2017 and December 31, 2016, respectively	6	6
Additional paid-in capital	170,224	169,391
Accumulated deficit	(162,131)	(158,238)
Accumulated other comprehensive loss	(17)	(12)
Total stockholders' equity	8,082	11,147
Total liabilities and stockholders' equity	$ 12,909	$ 18,871

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	58,144,888	58,144,888
Common stock, shares outstanding (in shares)	58,144,888	58,144,888

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract]
Revenue	$ 375	$ 375
Operating expense:
Research and development	475	450
Selling, general and administrative	3,806	8,543
Total operating expense	4,281	8,993
Loss from operations	(3,906)	(8,618)
Interest income, net	17	15
Loss before taxes	(3,889)	(8,603)
Provision for income taxes	(5)	(7)
Net loss	$ (3,894)	$ (8,610)
Basic and diluted loss per share (in dollars per share)	$ (0.07)	$ (0.16)
Weighted average shares outstanding basic and diluted (in shares)	58,145	54,135

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) [Abstract]
Net loss	$ (3,894)	$ (8,610)
Other comprehensive gain (loss), net of tax:
Change in equity adjustment from foreign currency translation, net of tax	(1)	0
Change in unrealized gain (loss) on investments, net of tax	(4)	9
Total other comprehensive gain (loss) net of tax	(5)	9
Comprehensive loss	$ (3,899)	$ (8,601)

XML 18 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (3,894)	$ (8,610)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	9	6
Amortization of warrant issuance costs	0	(30)
Stock-based compensation	833	1,234
Changes in assets and liabilities:
Prepaid expenses and other current assets	(185)	(108)
Accounts payable and accrued liabilities	(1,155)	1,643
Accrued payroll and related expenses	(1,372)	(1,383)
Related party payable	0	(11)
Income tax liability	5	0
Deferred revenue	(375)	(375)
Net cash used in operating activities	(6,134)	(7,634)
Cash flows from investing activities:
Purchase of property and equipment	0	(2)
Purchase of investments	0	(2,752)
Proceeds from sale or maturity of investments	3,116	4,116
Net cash provided by investing activities	3,116	1,362
Cash flows from financing activities:
Proceeds from exercise of options	0	20
Proceeds from sale of common stock	0	6,795
Net cash provided by financing activities	0	6,815
Net increase (decrease) in cash and cash equivalents	(3,018)	543
Cash and cash equivalents, beginning of period	6,627	8,726
Cash and cash equivalents, end of period	3,609	9,269
Cash paid for income taxes	$ 0	$ 0

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation	3 Months Ended
Business Description and Basis of Presentation	Mar. 31, 2017
Business Description and Basis of Presentation [Abstract]
Business Description and Basis of Presentation	Note 1 — Business Description and Basis of Presentation VirnetX Holding Corporation, which we refer to as “we”, “us”, “our”, “the Company” or “VirnetX”, is engaged in the business of commercializing a portfolio of patents. We seek to license our technology, including GABRIEL Connection Technology™, to various original equipment manufacturers, or OEMs, that use our technologies in the development and manufacturing of their own products within the IP-telephony, mobility, fixed-mobile convergence and unified communications markets. Prior to 2012 our revenue was limited to an insignificant amount of software royalties pursuant to the terms of a single license agreement. Since 2012 we had revenues from settlements of patent infringement disputes whereby we received consideration for past sales of licensees that utilized our technology, where there was no prior patent license agreement, as well as license agreement revenues from settlements providing licensing for the continued use of our technology (see “Revenue Recognition”). Our portfolio of intellectual property is the foundation of our business model. We currently own approximately 49 U.S. and 69 foreign patents with approximately 50 pending patent applications worldwide. Our patent portfolio is primarily focused on securing real-time communications over the Internet, as well as related services such as the establishment and maintenance of a secure domain name registry. Our patented methods also have additional applications in the key areas of device operating systems and network security for Cloud services, Machine-to-Machine (“M2M”), communications in areas including “Smart City,” “Connected Car” and “Connected Home.” All our U.S. and foreign patents and pending patent applications relate generally to securing communications over the internet and as such, cover all our technology and other products. Our issued U.S. and foreign patents expire at various times during the period from 2019 to 2024. Some of our issued patents and pending patent applications were acquired by our principal operating subsidiary, VirnetX, Inc., from Leidos, Inc. (“Leidos”) (f/k/a Science Applications International Corporation, or SAIC) in 2006 and we are required to make payments to Leidos based on cash or certain other values generated from those patents in certain circumstances. The amount of such payments depends upon the type of value generated and certain categories are subject to maximums and other limitations.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 — Summary of Significant Accounting Policies

Unaudited Interim Financial Information

Use of Estimates

Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

Revenue Recognition

Deferred revenue

Activity under the August 2013 Contract Settlement was as follows:

Deferred Revenue, December 31, 2016	$	4,000
Less: Amount amortized as revenue		375
Deferred Revenue, March 31, 2017	$	3,625

Earnings Per Share

Concentration of Credit Risk and Other Risks and Uncertainties

Prepaid Expenses

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

Mutual Funds: Valued at the quoted net asset value of shares held.

U.S. government and U.S. agency securities: Fair value measured at the closing price reported on the active market on which the individual securities are traded.

	March 31, 2017
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	1,947	$	—	$	—		$	1,947	$	1,947	$	—

Level 1:
Mutual funds		1,662		—		—			1,662		1,662		—
U.S. agency securities		6,133		—		(4	)		6,129		—		6,129
		7,795		—		(4	)		7,791		1,662		6,129
Total	$	9,742	$	—	$	(4	)	$	9,738	$	3,609	$	6,129

	December 31, 2016
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	3,432	$	—	$	—		$	3,432	$	3,432	$	—

Level 1:
Mutual funds		3,195		—		—			3,195		3,195		—
U.S. government securities		1,254		—		—			1,254		—		1,254
U.S. agency securities		7,996		2		(3	)		7,995		—		7,995
		12,445		2		(3	)		12,444		3,195		9,249
Total	$	15,877	$	2	$	(3	)	$	15,876	$	6,627	$	9,249

New Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606). This ASU was subsequently amended by ASU No. 2016-10 and 2016-12. As amended, Topic 606 supersedes the revenue recognition requirements in Topic 605,Revenue Recognition including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments create a new Subtopic 340-40,Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For a public entity, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are currently evaluating the impact this guidance will have on our financial position and statement of operations.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Taxes [Abstract]
Income Taxes	Note 3 — Income Taxes We had income tax expense of $5 and $7 for the three months ended March 31, 2017 and 2016, respectively, as a result of minimum tax payments. During the three month period ended March 31, 2017, we had net operating losses (“NOLs”) which generated deferred tax assets for NOL carry-forwards. We provided valuation allowances against the net deferred tax assets including the deferred tax assets for NOL carryforwards. Valuation allowances provided for our net deferred tax assets increased by approximately $1,786 and $3,342 for the three months ended March 31, 2017 and 2016, respectively. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets at March 31, 2017 will not be fully realizable. Accordingly, management has maintained a full valuation allowance against its net deferred tax assets at March 31, 2017. The valuation allowance carried against our net deferred tax assets was approximately $46,000 and $44,000 at March 31, 2017 and December 31, 2016, respectively. At March 31, 2017, we have federal and state net operating loss carry-forwards of approximately $78,000 and $61,000, respectively, expiring beginning in 2027 and began in 2016 for state, respectively. Our tax years for 2005 and forward are subject to examination by the U.S. tax authority and various state tax authorities. These years are open due to net operating losses and tax credits remaining unutilized from such years. Our policy is to recognize interest and penalties accrued on uncertain tax positions as a component of income tax expense. As of March 31, 2017, we had accrued immaterial amounts of interest and penalties related to the uncertain tax positions.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Commitments And Related Party Transactions	3 Months Ended
Commitments And Related Party Transactions	Mar. 31, 2017
Commitments And Related Party Transactions [Abstract]
Commitments And Related Party Transactions	Note 4 — Commitments And Related Party Transactions We lease our offices under an operating lease with a third party expiring in October 2017. We recognize rent expense on a straight-line basis over the term of the lease. We lease the use of an aircraft from K2 Investment Fund LLC (‘‘LLC’’) for business travel for employees of the Company. We incurred approximately $252 and $132 in rental fees and reimbursements to LLC during the three months ended March 31, 2017 and 2016, respectively. Our Chief Executive Officer and Chief Administrative Officer are the managing partners of the LLC and control the equity interests of LLC. On January 31, 2015, we entered into a 12-month non-exclusive lease with LLC for use of the plane at a rate of $8 per flight hour, with no minimum usage requirement. The agreement contains other terms and conditions normal in such transactions and can be cancelled by either us or LLC with 30 days’ notice. The lease renews on an annual basis unless terminated by the lessor or lessee. Neither party has exercised their termination rights.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Stock Based Compensation	3 Months Ended
Stock Based Compensation	Mar. 31, 2017
Stock Based Compensation [Abstract]
Stock Based Compensation	Note 5 — Stock Based Compensation We have a stock incentive plan for employees and others called the “VirnetX Holding Corporation 2013 Equity Incentive Plan”, or the Plan, which has been approved by our stockholders. The Plan provides for the granting of up to 14,124,469 shares of our common stock, including stock options and stock purchase rights (“RSUs”), and will expire in 2024. As of March 31, 2017, 396,221 shares remained available for grant under the Plan. During the three months ending March 31, 2017 we granted options for a total of 25,000 shares with a weighted average grant date fair value of $1.69. During the three months ended March 31, 2016 there were no grants of options or RSUs. Stock-based compensation expense included in general and administrative expense was $833 and $1,234 for the three months ended March 31, 2017 and 2016, respectively. As of March 31, 2017, the unrecognized stock-based compensation expense related to non-vested stock options and RSUs was $3,339 and $2,137, respectively, which will be amortized over an estimated weighted average period of approximately 2.54 and 2.20 years, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

Equity

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Equity

Note 6 — Equity

Common Stock

During the three months ended March 31, 2017, there were no shares sold under the ATM.

Warrants

Information about warrants outstanding during the three months ended March 31, 2017 follows:

Original Number of Warrants Issued		Exercise Price per Common Share		Exercisable at December 31, 2016		Became Exercisable		Exercised		Terminated / Cancelled / Expired		Exercisable at March 31, 2017		Expiration Date
	25,000	$	7.00		25,000		—		—		—		25,000	April 2020
					25,000		—		—		—		25,000

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Litigation	3 Months Ended
Litigation	Mar. 31, 2017
Litigation [Abstract]
Litigation	Note 7 — Litigation We have nine intellectual property infringement lawsuits pending in the United States District Court for the Eastern District of Texas, Tyler Division, and United States Court of Appeals for the Federal Circuit (“USCAFC”). VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) On March 30, 2015, the United States Court for the Eastern District of Texas, Tyler Division, issued an order finding substantial overlap between the remanded portions of the Civil Action Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.), and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. The jury trial in this case was held on January 25, 2016. On February 4, 2016, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us $625.6 million in a verdict against Apple Inc. for infringing four of our US patents, marking it the second time a federal jury has found Apple liable for infringing VirnetX’s patented technology. The verdict includes royalties awarded to us based on an earlier patent infringement finding (Case 6:10-CV-00417-LED) against Apple. The jury found that Apple’s modified VPN On-Demand, iMessage and FaceTime services infringed VirnetX’s patents and that Apple’s infringement was willful. In addition to determining the royalty owed by Apple for its prior infringement, this verdict also includes an award based on the jury’s finding that Apple’s modified VPN On Demand, iMessage and FaceTime services have continued to infringe VirnetX’s patents. The post-trial hearing was held on May 25, 2016 in the United States Court for the Eastern District of Texas, Texarkana Division. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases (Case No. 6:10-cv-417, Docket No. 878 (“Apple I case”); Case No. 6:12-cv-855, Docket No. 220 (“Apple II case”)), ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II case will be retried after Apple I case. Events and developments subsequent to the order from the court are described to support Apple I and Apple II matters. VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) (“Apple I”) On August 11, 2010, we initiated a lawsuit by filing a complaint against Aastra USA. Inc. (“Aastra”), Apple, Cisco Systems, Inc. (“Cisco”), and NEC Corporation (“NEC”) in the United States District Court for the Eastern District of Texas, Tyler Division, pursuant to which we alleged that these parties infringe on certain of our patents. We sought damages and injunctive relief. Aastra and NEC agreed to sign license agreements with us and we agreed to drop all the accusations of infringement against them. At the pre-trial hearing, the judge decided to conduct separate jury trial for each defendant, and try only the case against Apple on the scheduled trial date. The jury trial of our case against Cisco was held on March 4, 2013. The jury in our case against Cisco came back with a verdict of non-infringement also determined that all our patents-in-suit patents are not invalid. Our motions for a new trial and Cisco’s infringement of certain VirnetX patents were denied and the case against Cisco was closed. The jury trial of our case against Apple was held on October 31, 2012. On November 6, 2012, a jury in the United States Court for the Eastern District of Texas, Tyler Division, awarded us over $368 million in a verdict against Apple for infringing four of our patents. On February 26, 2013, the court issued its Memorandum Opinion and Order regarding post-trial motions resulting from the prior jury verdict denying Apple’s motion to reduce the damages awarded by the jury for past infringement. The Court further denied Apple’s request for a new trial on the liability and damages portions of the verdict and granted our motions for pre-judgment interest, post-judgment interest, and post-verdict damages to date. The Court ordered that Apple pay $34 thousand in daily interest up to final judgment and $330 thousand in daily damages for infringement up to final judgment for certain Apple devices included in the verdict. The Court denied our request for a permanent injunction and severed the future infringement portion into its own separate proceedings under Case 6:13-CV-00211-LED. On July 3, 2013, Apple filed an appeal of the judgment dated February 27, 2013 and order dated June 4, 2013 denying Apple’s motion to alter or amend the judgment to the USCAFC. On September 16, 2014, USCAFC issued their opinion, affirming the jury’s finding that all 4 of our patents are valid, confirming the jury’s finding of infringement of VPN on Demand under many of the asserted claims of our ‘135 and ‘151 patents, and confirming the district’s court’s decision to allow evidence concerning our licenses and royalty rates in connection with the determination of damages. In its opinion, the USCAFC also vacated the jury’s damages award and the district court’s claim construction with respect to parts of our ‘504 and ‘211 patents and remanded the damages award and determination of infringement with respect to FaceTime –for further proceedings consistent with its opinion. On October 16, 2014, we filed a petition with the USCAFC, requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision concerning VirnetX’s litigation against Apple Inc. On December 16, 2014, USCAFC denied our petition requesting a rehearing and rehearing en banc of the Federal Circuit’s September 14, 2014, decision and remanded the case back to the Eastern District of Texas, Tyler Division, for further proceedings consistent with its opinion. On February 25, 2015, USCAFC granted Apple’s motions to lift stay of proceedings and vacate Case 6:13-CV-00211-LED. On March 30, 2015, the court issued an order finding substantial overlap between the remanded portions of this case and the ongoing Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case. The jury trial in this case was held on September 26, 2016. On September 30, 2016, a Jury in the United States Court for the Eastern District of Texas, Tyler Division, in the case VirnetX Inc., et al. v. Apple Inc., No. Apple I, has awarded VirnetX $302.4 million in a verdict against Apple for infringing four VirnetX patents, marking the third time a federal jury has found Apple liable for infringing VirnetX’s patented technology. The verdict includes royalties awarded to VirnetX, for unresolved issues in the Apple I case, remanded back from the USCAFC, related to (1) damages owed to VirnetX for infringement by Apple’s original VPN-on-Demand (VOD) and (2) the alleged infringement by Apple’s original FaceTime product, under the new claim construction of “secure communication link” pertaining to the ’504 and ’211 patents by the USCAFC, and the damages associated with that infringement. The hearing on all the post-trial motions was held on November 22, 2016. We are currently awaiting the court ruling and final judgement in this case. VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) (“Apple II”) On November 6, 2012, we filed a new complaint against Apple in the United States District Court for the Eastern District of Texas, Tyler Division for willfully infringing four of our patents, U.S. Patent Nos. 6,502,135, 7,418,504, 7,921,211 and 7,490,151, and seeking both an unspecified amount of damages and injunctive relief. The accused products include the iPhone 5, iPod Touch 5th Generation, iPad 4th Generation, iPad mini, and the latest Macintosh computers. Due to their release dates, these products were not included in the previous lawsuit that concluded with a Jury verdict on November 6, 2012 that was subsequently upheld by the United States District Court for the Eastern District of Texas, Tyler Division, on February 26, 2013. On July 1, 2013, we filed a consolidated and amended complaint to include U.S. Patent No. 8,051,181 and consolidate Civil Action No. 6:11-cv-00563-LED. On August 27, 2013, we filed an amended complaint including allegations of willful infringement related to U.S. Patent No. 8,504,697 seeking both damages and injunctive relief. The Markman hearing in this case was held on May 20, 2014 and on August 8, 2014, issued its Markman Order, denying Apple’s motion for summary judgment of indefiniteness, in which Apple alleged that some of the disputed claims terms in the patents asserted by us were invalid for indefiniteness. In a separate order, the court granted in part and denied in part our motion for partial summary judgment on Apple’s invalidity counterclaims, precluding Apple from asserting invalidity as a defense against infringement of the claims that were tried before a jury in our prior litigation against Apple (VirnetX vs. Cisco et. al., Case 6:10-CV-00417-LED). The jury trial in this case was scheduled for October 13, 2015. On March 30, 2015, the court issued an order finding substantial overlap between this case and the remanded portions of Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.). The court consolidated the two civil actions under Civil Action Case 6:12-CV-00855-LED (VirnetX Inc. v. Apple, Inc.) and designated it as the lead case. On July 29, 2016, the court issued a new order, vacating its previous orders consolidating the cases Apple I case and Apple II case, ordering that the two cases be retried separately, and setting the retrial date for Apple I case with jury selection to begin on September 26, 2016. The court also ordered that the issue of willfulness in both cases is bifurcated and that the Apple II will be retried after Apple I case. We are awaiting court order setting the date for a new jury trial in Apple II case. VirnetX Inc. v. Apple, Inc. (Case 15-1934) On July 10, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the United States Patent and Trademark Office, Patent Trial and Appeal Board (“PTAB”) in IPR2014-00237 and IPR2014-00238, related to U.S. Patent No. 8,504,697. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00238. We are currently evaluating our options in this case. VirnetX Inc. v. Apple, Inc. (Case 16-1211) On September 28, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2014-00403 and IPR2014-00404 and on October 22, 2015 for IPR2014-00481 and IPR2014-00482 involving our U.S. Patent Nos. 7,188,180, and 7,987,274. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on the grounds discussed in IPR2014-00403 and IPR2014-00481. We are currently evaluating our options in this case. VirnetX Inc. v. Apple, Inc. (Case 16-1480) On November 30, 2015, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in inter-partes reexamination no. 95/001,949 related to U.S. Patent No. 8,051,181. The oral arguments in this case were heard on November 7, 2016. On December 9, 2016, the USCAFC affirmed the PTAB based on certain grounds. We are currently evaluating our options in this case. VirnetX Inc. v. Apple, Inc. (case 16-119) On March 4, 2016, we filed a petition for writ of mandamus with the USCAFC, requesting the USCAFC’s intervention to revoke the PTAB’s decision joining Apple to IPR2015-01046 and IPR2015-01047, related to U.S. Patent Nos. 6,502,135 and 7,490,151. On March 18, 2016, the USCAFC denied the petition without prejudice to us raising the arguments on appeal after the PTAB’s final decisions. We are currently evaluating our options in this case. VirnetX Inc. v. Apple, Inc. (Case 17-1131) On October 31, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-00810, IPR2015-00812, on November 9, 2016 for IPR2015-00811, and on November 28, 2016 for IPR2015-00866, IPR2015-00868, IPR2015-00870, IPR2015-00871 involving our U.S. Patent Nos.8,868,705, 8,850,009, 8,458,341, 8,516,131, and 8,560,705. These appeals have been consolidated. VirnetX Inc. v. The Mangrove Partners (Case 17-1368) On December 16, 2016, we filed appeals with the USCAFC, appealing the invalidity findings by the PTAB in IPR2015-01046, and on December 20, 2016 for IPR2015-1047, involving our U.S. Patent Nos. 6,502,135, and 7,490,151. These appeals also involve Apple, Inc. and one of them involves Black Swamp IP, LLC. One or more potential intellectual property infringement claims may also be available to us against certain other companies who have the resources to defend against any such claims. Although we believe these potential claims are worth pursuing, commencing a lawsuit can be expensive and time-consuming, and there is no assurance that we will prevail on such potential claims. In addition, bringing a lawsuit may lead to potential counterclaims which may preclude our ability to commercialize our initial products, which are currently in development. Currently, we are not a party to any other pending legal proceedings, and are not aware of any proceeding threatened or contemplated against us by any governmental authority or other party.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Unaudited Interim Financial Information

Use of Estimates

Basis of Consolidation

The consolidated financial statements include the accounts of VirnetX Holding Corporation and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

Revenue Recognition

Deferred revenue

Activity under the August 2013 Contract Settlement was as follows:

Deferred Revenue, December 31, 2016	$	4,000
Less: Amount amortized as revenue		375
Deferred Revenue, March 31, 2017	$	3,625

Earnings Per Share

Concentration of Credit Risk and Other Risks and Uncertainties

Prepaid Expenses

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

Mutual Funds: Valued at the quoted net asset value of shares held.

U.S. government and U.S. agency securities: Fair value measured at the closing price reported on the active market on which the individual securities are traded.

	March 31, 2017
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	1,947	$	—	$	—		$	1,947	$	1,947	$	—

Level 1:
Mutual funds		1,662		—		—			1,662		1,662		—
U.S. agency securities		6,133		—		(4	)		6,129		—		6,129
		7,795		—		(4	)		7,791		1,662		6,129
Total	$	9,742	$	—	$	(4	)	$	9,738	$	3,609	$	6,129

	December 31, 2016
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	3,432	$	—	$	—		$	3,432	$	3,432	$	—

Level 1:
Mutual funds		3,195		—		—			3,195		3,195		—
U.S. government securities		1,254		—		—			1,254		—		1,254
U.S. agency securities		7,996		2		(3	)		7,995		—		7,995
		12,445		2		(3	)		12,444		3,195		9,249
Total	$	15,877	$	2	$	(3	)	$	15,876	$	6,627	$	9,249

New Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606). This ASU was subsequently amended by ASU No. 2016-10 and 2016-12. As amended, Topic 606 supersedes the revenue recognition requirements in Topic 605,Revenue Recognition including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments create a new Subtopic 340-40,Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For a public entity, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are currently evaluating the impact this guidance will have on our financial position and statement of operations.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies [Abstract]

Schedule of Deferred Revenue

Activity under the August 2013 Contract Settlement was as follows:

Deferred Revenue, December 31, 2016	$	4,000
Less: Amount amortized as revenue		375
Deferred Revenue, March 31, 2017	$	3,625

Cash and Available-for-Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses and Fair Value by Significant Investment Category

	March 31, 2017
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	1,947	$	—	$	—		$	1,947	$	1,947	$	—

Level 1:
Mutual funds		1,662		—		—			1,662		1,662		—
U.S. agency securities		6,133		—		(4	)		6,129		—		6,129
		7,795		—		(4	)		7,791		1,662		6,129
Total	$	9,742	$	—	$	(4	)	$	9,738	$	3,609	$	6,129

	December 31, 2016
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Investments Available for Sale
Cash	$	3,432	$	—	$	—		$	3,432	$	3,432	$	—

Level 1:
Mutual funds		3,195		—		—			3,195		3,195		—
U.S. government securities		1,254		—		—			1,254		—		1,254
U.S. agency securities		7,996		2		(3	)		7,995		—		7,995
		12,445		2		(3	)		12,444		3,195		9,249
Total	$	15,877	$	2	$	(3	)	$	15,876	$	6,627	$	9,249

XML 28 R16.htm IDEA: XBRL DOCUMENT

Equity (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Information about Warrants Outstanding

Information about warrants outstanding during the three months ended March 31, 2017 follows:

Original Number of Warrants Issued		Exercise Price per Common Share		Exercisable at December 31, 2016		Became Exercisable		Exercised		Terminated / Cancelled / Expired		Exercisable at March 31, 2017		Expiration Date
	25,000	$	7.00		25,000		—		—		—		25,000	April 2020
					25,000		—		—		—		25,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Business Description and Basis of Presentation (Details)	Mar. 31, 2017 Patent
Finite-Lived Intangible Assets [Line Items]
Number of pending patent applications	50
Patents [Member] \| U.S. [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents owned	49
Patents [Member] \| Foreign [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents owned	69

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) Institution	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Patent License Agreements [Abstract]
Threshold period of payment of fees after delivery for fees to be generally presumed not to be fixed or determinable, and for revenue to be deferred and recognized as earned	12 months
Concentration of Credit Risk and Others Risks and Uncertainties [Abstract]
Number of financial institutions holding company's cash \| Institution	2
Prepaid Expenses [Abstract]
Prepayment of facility lease for corporate promotional and marketing purposes	$ 4,000
Lease term	10 years
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Adjusted Cost	$ 3,609	$ 9,269	$ 6,627	$ 8,726
Adjusted Cost	7,795		12,445
Unrealized Gains	0		2
Unrealized Losses	(4)		(3)
Fair Value	7,791		12,444
Adjusted Cost	9,742		15,877
Fair Value	9,738		15,876
Investments Available for Sale	7,791		12,444
Cash [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Adjusted Cost	1,947		3,432
Fair Value	1,947		3,432
Cash and Cash Equivalents	1,947		3,432
Mutual Funds [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Adjusted Cost	1,662		3,195
Unrealized Gains	0		0
Unrealized Losses	0		0
Fair Value	1,662		3,195
Investments Available for Sale	1,662		3,195
U.S. Government Securities [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Adjusted Cost			1,254
Unrealized Gains			0
Unrealized Losses			0
Fair Value			1,254
Investments Available for Sale			1,254
U.S. Agency Securities [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Adjusted Cost	6,133		7,996
Unrealized Gains	0		2
Unrealized Losses	(4)		(3)
Fair Value	6,129		7,995
Investments Available for Sale	6,129		7,995
Recurring [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value	3,609		6,627
Fair Value	6,129		9,249
Cash and Cash Equivalents	3,609		6,627
Investments Available for Sale	6,129		9,249
Recurring [Member] \| Cash [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value	1,947		3,432
Cash and Cash Equivalents	1,947		3,432
Recurring [Member] \| Level 1 [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value	1,662		3,195
Fair Value	6,129		9,249
Cash and Cash Equivalents	1,662		3,195
Investments Available for Sale	6,129		9,249
Recurring [Member] \| Level 1 [Member] \| Mutual Funds [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value	1,662		3,195
Fair Value	0		0
Cash and Cash Equivalents	1,662		3,195
Investments Available for Sale	0		0
Recurring [Member] \| Level 1 [Member] \| U.S. Government Securities [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value			0
Fair Value			1,254
Cash and Cash Equivalents			0
Investments Available for Sale			1,254
Recurring [Member] \| Level 1 [Member] \| U.S. Agency Securities [Member]
Cash and available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category [Abstract]
Fair Value	0		0
Fair Value	6,129		7,995
Cash and Cash Equivalents	0		0
Investments Available for Sale	$ 6,129		$ 7,995
August 2013 Contract [Member]
Deferred Revenue [Abstract]
Term of contract	4 years
Contract amount	$ 10,000
Activity under August 2013 contract settlement [Roll Forward]
Deferred Revenue, beginning of period	4,000
Less: Amount amortized as revenue	375	$ 375
Deferred Revenue, end of period	$ 3,625

XML 31 R19.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Taxes [Abstract]
Income tax expense	$ 5	$ 7
Net change in valuation allowance	1,786	$ 3,342
Valuation allowance carried against net deferred tax assets	46,000		$ 44,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 78,000
Operating loss carryforwards, expiration dates	Dec. 31, 2027
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 61,000
Operating loss carryforwards, expiration dates	Dec. 31, 2016

XML 32 R20.htm IDEA: XBRL DOCUMENT

Commitments And Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Leased Assets [Line Items]
Term of lease	10 years
Offices [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Oct. 31, 2017
K2 Investment Fund LLC [Member] \| Aircraft [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Jan. 31, 2015
Rental fees incurred for use of aircraft	$ 252	$ 132
Term of lease	12 months
Rate of aircraft lease (in dollars per flight hour)	$ 8
Term of notice for cancellation of lease	30 days

XML 33 R21.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 833	$ 1,234
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 833	$ 1,234
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	25,000	0
Options granted, weighted average grant date fair value (in dollars per share)	$ 1.69
Unrecognized stock-based compensation expense expected to be recognized related to non-vested stock options	$ 3,339
Weighted average amortization period	2 years 6 months 14 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs granted (in shares)		0
Unrecognized stock-based compensation expense expected to be recognized related to non-vested RSUs	$ 2,137
Weighted average amortization period	2 years 2 months 12 days
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)	14,124,469
Shares available for grant (in shares)	396,221

XML 34 R22.htm IDEA: XBRL DOCUMENT

Equity, Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	19 Months Ended
	Mar. 31, 2017	Mar. 31, 2017	Aug. 21, 2015	Aug. 20, 2015
Universal Shelf Registration Statement [Member]
Common Stock [Abstract]
Securities offered for sale, aggregate value			$ 100,000
ATM Agreement [Member]
Common Stock [Abstract]
Securities offered for sale, aggregate value				$ 35,000
Average sales price per common share (in dollars per share)		$ 4.14
Aggregate proceeds from sales of common stock		$ 23,169
ATM Agreement [Member] \| Common Stock [Member]
Common Stock [Abstract]
Number of shares of common stock sold (in shares)	0	5,595,650
Sales commissions, fees and other costs associated with issuance of common stock		$ 695

XML 35 R23.htm IDEA: XBRL DOCUMENT

Equity, Warrants (Details) - Warrants [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares shares
Information about warrants outstanding [Abstract]
Exercisable, beginning of period (in shares)	25,000
Became exercisable (in shares)	0
Exercised (in shares)	0
Terminated/cancelled/expired (in shares)	0
Exercisable, end of period (in shares)	25,000
Advisor Warrants [Member]
Warrants [Abstract]
Life of service contract	12 months
Fair value of warrants issued \| $	$ 121
Fair value assumptions used in estimating fair value of warrants [Abstract]
Dividends yield of common stock	0.00%
Expected stock price volatility	87.50%
Risk-free interest rate	1.33%
Expected term	5 years
Information about warrants outstanding [Abstract]
Original number of warrants issued (in shares)	25,000
Exercise price per common share (in dollars per share) \| $ / shares	$ 7.00
Exercisable, beginning of period (in shares)	25,000
Became exercisable (in shares)	0
Exercised (in shares)	0
Terminated/cancelled/expired (in shares)	0
Exercisable, end of period (in shares)	25,000
Expiration date	April 30, 2020

XML 36 R24.htm IDEA: XBRL DOCUMENT

Litigation (Details) - Positive Outcome of Litigation [Member] $ in Thousands	Sep. 30, 2016 USD ($) Patent	Jul. 29, 2016 Case	Feb. 04, 2016 USD ($) Patent	Mar. 30, 2015 Action	Feb. 26, 2013 USD ($)	Nov. 06, 2012 USD ($) Patent	Mar. 31, 2017 Lawsuit
Gain Contingencies [Line Items]
Number of intellectual property infringement lawsuits pending \| Lawsuit							9
VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) [Member]
Gain Contingencies [Line Items]
Number of civil actions consolidated by court \| Action				2
Amount of damages awarded in patent infringement case			$ 625,600
Number of patents allegedly infringed upon by Apple, Inc. \| Patent			4
Number of cases ordered to be retried by court \| Case		2
VirnetX Inc. v. Cisco Systems, Inc. et al. (Case 6:10-CV-00417-LED) ("Apple I") [Member]
Gain Contingencies [Line Items]
Number of civil actions consolidated by court \| Action				2
Amount of damages awarded in patent infringement case	$ 302,400					$ 368,000
Number of patents allegedly infringed upon by Apple, Inc. \| Patent	4					4
Number of cases ordered to be retried by court \| Case		2
Amount of interest payment awarded up to final judgment, per day					$ 34
Amount of damage infringement payment awarded up to final judgment, per day					$ 330
VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED) ("Apple II") [Member]
Gain Contingencies [Line Items]
Number of civil actions consolidated by court \| Action				2
Number of patents allegedly infringed upon by Apple, Inc. \| Patent						4
Number of cases ordered to be retried by court \| Case		2

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 70 156 1 false 28 0 false 9 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://virnetx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://virnetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://virnetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://virnetx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) Sheet http://virnetx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://virnetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 060100 - Disclosure - Business Description and Basis of Presentation Sheet http://virnetx.com/role/BusinessDescriptionAndBasisOfPresentation Business Description and Basis of Presentation Notes 7 false false R8.htm 060200 - Disclosure - Summary of Significant Accounting Policies Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 060300 - Disclosure - Income Taxes Sheet http://virnetx.com/role/IncomeTaxes Income Taxes Notes 9 false false R10.htm 060400 - Disclosure - Commitments And Related Party Transactions Sheet http://virnetx.com/role/CommitmentsAndRelatedPartyTransactions Commitments And Related Party Transactions Notes 10 false false R11.htm 060500 - Disclosure - Stock Based Compensation Sheet http://virnetx.com/role/StockBasedCompensation Stock Based Compensation Notes 11 false false R12.htm 060600 - Disclosure - Equity Sheet http://virnetx.com/role/Equity Equity Notes 12 false false R13.htm 060700 - Disclosure - Litigation Sheet http://virnetx.com/role/Litigation Litigation Notes 13 false false R14.htm 070200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://virnetx.com/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 080200 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://virnetx.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 080600 - Disclosure - Equity (Tables) Sheet http://virnetx.com/role/EquityTables Equity (Tables) Tables http://virnetx.com/role/Equity 16 false false R17.htm 090100 - Disclosure - Business Description and Basis of Presentation (Details) Sheet http://virnetx.com/role/BusinessDescriptionAndBasisOfPresentationDetails Business Description and Basis of Presentation (Details) Details http://virnetx.com/role/BusinessDescriptionAndBasisOfPresentation 17 false false R18.htm 090200 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://virnetx.com/role/SummaryOfSignificantAccountingPoliciesTables 18 false false R19.htm 090300 - Disclosure - Income Taxes (Details) Sheet http://virnetx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://virnetx.com/role/IncomeTaxes 19 false false R20.htm 090400 - Disclosure - Commitments And Related Party Transactions (Details) Sheet http://virnetx.com/role/CommitmentsAndRelatedPartyTransactionsDetails Commitments And Related Party Transactions (Details) Details http://virnetx.com/role/CommitmentsAndRelatedPartyTransactions 20 false false R21.htm 090500 - Disclosure - Stock Based Compensation (Details) Sheet http://virnetx.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) Details http://virnetx.com/role/StockBasedCompensation 21 false false R22.htm 090600 - Disclosure - Equity, Common Stock (Details) Sheet http://virnetx.com/role/EquityCommonStockDetails Equity, Common Stock (Details) Details 22 false false R23.htm 090602 - Disclosure - Equity, Warrants (Details) Sheet http://virnetx.com/role/EquityWarrantsDetails Equity, Warrants (Details) Details 23 false false R24.htm 090700 - Disclosure - Litigation (Details) Sheet http://virnetx.com/role/LitigationDetails Litigation (Details) Details http://virnetx.com/role/Litigation 24 false false All Reports Book All Reports vhc-20170331.xml vhc-20170331.xsd vhc-20170331_cal.xml vhc-20170331_def.xml vhc-20170331_lab.xml vhc-20170331_pre.xml true true ZIP 43 0001140361-17-018829-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-17-018829-xbrl.zip M4$L#!!0 ( &2 J$J-+.(*A)4 (]*!P 0 =FAC+3(P,3W/;N)+O_UNUWP'KG;,WJ9(E(U3S!,DO'K5Z_N[NX.\M1J-]BL1Q E4SP_4]T#@]WL^Q]<])\X^_S'S M_5V;OH:.G+ZBM]FGL2C[$*IMOOJO3YF^DB_UIR(. M.ZWF\7V=E5]D!8);'B?%NF/N'@["VU?R'11KMNN-9KW=U(5@F >.,\Y*]9VX M1RVH%UBD6RSB<5'>"+S SSM3+231W#Z;1A'(Q[QRZFU)P< 1;EQ>BEYAD6:Q M2"S<\@+PHNSS9!S-^1[>E!3@/]QA>0%\4]*'VV%.T*V( I[\.'3#$7YYW&AG MWRTCFB#2C/V,LO0Z)BGYPON,9.LUCMC;@UB,QCZ*##T;1KS_]@#:K^NV#G_$ MW@%[)>LAC0!#&B3\1\*$]_; I>^:C6829M31M]G7'/1.,E'/LJ?"P^=]P2-& M=/%"9S1_SC_^X^"7!DAYXZ35;G5^?C5=6#?UJJ0MU=(8T!AZT^T#>Z+D/6C8 M7Y!L9'^CJ6O)WTT5XH%G%&G#B.4->T8!_=1H6C]2O+N?G4>-H[U@HD19HOAQ M!/]DE:LWZ^!'M]G:$U 9_.C6FRT#'^ODQ_X(61$?[0WQHYNIG^[><*:@?KJK MJY_NYM3/T3Z*V]'FQ&U_0%50/QL3-U(_?\#,0B3\4L#$X6, =0]$S^=G<2,A\)]+^(D$KTT@2D1 M??CM9@=\SF62#T8\8U+VP@,R?HQ]X8I$]H!Y KZ3\SCEN+^>WZF#7Y23^_K; MS<^O2BM\4(LK#,#!+[I0820649/IHP)?JFH%-@C+SV'P37WV%/&IOS&Z:8&Z M2: 69DM_O.=]#K-9[PN_Y4'*SZ((>,2Q(U]A@D8 _!).'#^9G TB3B_V'(R+ M>YP#84[7MP6)"D\3:5IDT5-E]&QG/C@U_[&0J#(D*CSQL^:H\NC94D"%+,N% M(Z+?'#_E[R;DK>6.\[D3#_=[R.?V+1_IO)-/RUJH>9(=W.11@ M5][S7G+#W302B>![KL*7&/)%77]>4OXI35+'OT@#[\D/_'17GY?$VX%^)A+] M[>9KQ)TXC2;/2JG/Z_3SDG([^+L>_$W&=QX\^&:A[.=_PD@YD3N<7,)\UZ<: MLG(NO\INY6V=*[H6PIN# M\'-'IP7)$C,+ZW78Z4+%X+_Y?2G6S%LS_V0@_-S1:4&RSOP4ZQL\!]_@F2V> M[Z/P?@S<<,2_.C_.TF08PE!(N;E)G(2?!=YEZ#K^WV&(8D^XN'UTOT6FO+]PKN,E\2*M1&[M!%[ MA)_K*(2*DLFU#]H,./?AKU2,L?/O)MG^TG>I\+V]=\F7Z&D.I&*7+6YF<$-Z MF4=C(&KRV1E)H/RC]9&.VB1?/@4QO#Q7\\%E8'8FHJ^1$\3C, (QAK'+/MIO MX)6QZN"7VZ'[>BZ_UCG56@GWB\; 2L+,\0Y6$JPD/.<#*I";&>[Q#SQG>;]Q M:G9)XK/8KZ_SE$H7NYO,_MIQ7T M&>?/(F3W"*FV4U1$R!>.9QRZ"?>(=]\"D<1?;KX]293K2V:0(D,Z%+C! M+F/D)COH4]ZZX8.K=N:-1( G9<++6_[AQQA&@^\W?N[I>(ZFI3A@434G+&I1 MM6^HJI95L][.#KV=;2ZT6G=EI^[*;I99[:!7QT>MEMX_@K%I_G&3]F+A"2>: MW#@^O^H3KV3N7"#PYCC'OQERO_^%#Y0%#8/,\.XW;N9V74;#EN[_#A3(4;UQ M4F]M1($@+!KWP.+LZZ?L(-HG/?ZS'=W90#"Y$'0&2EQN\;$&-WPO3([,2V2:"V*F+;IKT@BVV+[:?D MMQ7TML7J[DSU'NG XDSP=P=O'%!L^8.V2%SUU<.KZ O>TBPQY-V*.(S4FST_ MWW-N-Q6,ROJZ3JTW9Z9:& NKX2Q>UXF77OYM\=I(T M4IG!82PPQ^ J33!#X:I_"7\.G/U?/[^WV\8-NHOZ_[0@<020:)">IU^/!<7WYX M?S8>^_SC?F-ME@O247D$*];ISNR;*$R'J$ 8&JM8QZDBZPUE;E-^)" "5R*E MA4@Y.3K*D++G4K,M6*Y9DI<;%"LK59$5*R15$A(K'5G"_:F2#OIE/;'G+"[K M]@XW(C_=>N-T1?F9*K).^6DUFXTNR0_]LO)C9S(5G\FTZLUFO=%=17ZFBJS7 M_K0:'65_X)?USJKI"3T;Z0!3T:HW.BM:%[/(_EJ7ISW/W]J<^MG(2M4LR7'K M5%D2^&5EQRYQ^3\5E M7V)B%9*?=J/5DK,6^F7EQ\I/Q>6GC5/XUDHSF:DBCY&?-!!2>+X!E*;@.9*7 M6ORB"!LZ$8]U5?J=63W6-:_NUIRZ11QV6LWCU]]NWC^TZO94U9ZX!2F89A^6 M^)R.>.0DX0S@EJ;'9'!YC49S[WD0CD1P?X.+F#O=XFRE^JW1[V78UIDS(G2H M), I2!XZ($?WU/PQB$%*4A3;AU;?O1>F8_CYT)J/[R'\TKF+4_%@GIS<4_69 M^QAVG-Y3,VJ[Y>K]MWK]#'2:AWJ-7?C.H%Z7+SPN7F=O\ 536N0+[Y1I%U [H9\=G_\V=B'T(/(9:S&Q7?2<_PZ\^2$VWF(2ZSA._ MKYJ,GO>AFU+'KTEGEM*BOY&?+$V(F%BRCZ'DJ)[JYFF[+?03P.P4!,8.Y]'\2P] MV1?R@U7IF"H^W;Y&SA>.IQ^#.\)P4W):0H?Z,OM0?K>8G/]&-;RHFFFRB%AV M#D,Y"*/)+#'T7K]>3,.9ZW(?[0J,.Q4U*2K4-4V(/O$$6(3'!,]2DG^ [Q>3 MHKPI]I^AC[<.L/,P&IO4%.N;&2Y@7002_C'P^ _V#U["&O4)?0$?+*;(]'GG M5C-#".U)9[0%N<9NR-HR<%,QK1C[54)7OHM=?FY\74+D$5@]ANJ4GI$SQ3SN MBA'HPK<''S]?'/QR=-+L=$Y.3@IDW]/*K'HR]>4%/(S+%%2NYNB3Y51443E- M53&7$*4N%Y BOUJ2F/_7+"/%J&*6&-S04-8Z/E_<8+-1_W_%)K%<;A1=%X^& MC]FU,W%Z/F1BG(YJ5P>L*GB^AJ6C5I2K(]%ZH"51Y/-I2EC<):JTT3 M2[OABK!JF;"J@^O;/&ET021^?O6 !JO12SD0]_>R>]1\="?E 90L<7XP7WTU M*>D'UI+=YO.XL6F?S@Q->>T;HG$9SG8:,YQ=0"-\D8Y2GZS353)$PQ>.QA$? MX@S]EC/5AQ>781R_K+'//&%AGT%5)1W1%5$]A6ID+5@'5'#5A^(/&@+P Z>[ MMTJ;U>OT,F-:AZ_6TFG/$S@U 54_=H17%P%SG;%(''^F5]F7U_#AQ^!89>7Y^Q_9$3J?^MG(F+%6T!8=@U(_M5TYU7MD@J\ MC4QZ&A=(S@P'*G";S +^MZ=D^Y[N[>,(5.%FJ_M'H'7T@!$@;[?> M/-B9FI[AE>_C&='<(\_X'7Y_;GRNCH1>A-M%&&JUIU3-4JUNJS/3[NK]G3EI MMS?2%W4JM_0*"^=R,TWX7,"O91#7<&KZCF"P?=:M_\#YC8*.;ON.9_I.3Q_F M/K1.&Z=%BJBRA[6XW!3LY+BYN,7YDR=Z_:A)8+?3[910,..Z/X:0I9@/D]'N M,H3<.L+'F5L=3&\]=F#*F5_J7O]VP_15[\;C^8*B*[L((SQJSBA2RLP_YEXV M_\?\.^87=/SX]/2HV.^Y1"W)A$]IDH+B(,=C#3V7RF!^SV5SV-IR"K/;;56Z MOXM&>L7^MIOK'M]OAS>'[-?PED]'O>2U:$>[-UU%DS.S8F\XN0 M_V"9[Z*I62L3'CG>"P>MTUGSJ#UR5!8IU>/IZ?5CZ444,()!#69WXQ2-X26_ MY3YKYE#[@M]'&.?/'E71(IF%LI__*<"AB]SAA'I%-63O9(?I17.VBD]R?9CF MD1'_*^6!.RF6-[Z(,QY5R3J6#-Q2 [X]J[I'8[;.T2H9F#5*S":Y<-KJK%G' M+V/WMP_DQ_H+>P3L]?LN%= [%>?Y^EVEBAB 5:<9>S1F59"0*LX*]F@(UR]V M#W6@URAA%>?Y^CV&M;)S!O=[A;\:,Q?B?XW".&;? A!47_P3'S@BJ+$>AY*\ M=/%];O-&M51K7BG6^8YJ?.AR_%+]7Y* S;!I;6KV46S<1(RF^KQ_7-QS4PQ? M,3Q:?3;O'.(;6WI8-@Z_4_9OA[U/@5.[T0=K7BZI/IO7NORR.9WPJ%6:RHT" M9AGN8A2PW7T=A0+M&QJ%S=O&QX[ VUC^]$:_SFP?V/>][)QUIVR?U,&]W$\ MWZ[!W0*;M\-1"\A-Z6 +R =QM*(&:H3;69$MYV&#/[O+9ERC^*W-S7T4E!Z1 M[C>=Z;X%IJT3/TND!SY95&PR\;N[2::A=2@\.)^3NS^WV:)].7_$-H,5EC9+ M&ZU:GY?:>;[\$N;]?;Y)1R,\."7LLQLQ"$1?N'A,A]K)CJN[UR$>.C:;54N" M@JOD(WW_FA^WWQ 0C_X2=O/''+XF3B\[<'??B^ MWG=&PI^\9O_GJQB!,'[F=^Q+.'*"__.&T?L84/R:-1OCY,W!?PR2-V5U&-^P MI2J]XWC'[6O6"WWO#4.BZ^#A#H+7S.=]U=#G,.&LQ?[#&8W?_/M)J]EZ(W\V MNXTW;'D.([VO@&"#=OVS%[%7^O?4)^OLGJP#ZWO-<(>P<(M=_C.-$]&?R%Y_ M"YS4$SBK^8@;0,6(78C "5Q!1ZN "(T(%%ONU5QROPXY+:EC0JJ M#?C #"J3#"/.V0BZ,(P9A_+>5-6T(P_UW@IM%+?\X\3K0>WAK^7;=.(AN_## MNX>TQ1R8ZZ8:/8<,1B8V'C"AX.2:[?MSC/&# @;$346$:YO(M$%F/8_9"BW6K\4;.U<[. MKK-GS31RCAM$CT<=LJ+&AE[$")#!O=$QG8L*;*"GQ,$Q]#SL)#B5)"93Y,PWHD#\I)LB/Q17A M>$1<1K. OSQ#+56*PWP6!#CCE(>3,:@=7)(1]+S^CQRA\J0FY*T:]?VQZ91]M,>9S#!W@T0NU2%6#]SK4&E9*Z MA*J:4;.9B1/@4(MJ'8*^^;A3Q&_Y4&*O[!*+G=RXU\Q-(V:-,X ZP'N_!#3 M!K$V5Y\=G*B*J0*C;NI(C 8<5!=6>8<2@G(4T7F$X&]/I U*8ZH=J">7WC0O MRKF3Q.G>S]3L#AV@)-8R9%1@<"SB9L.^^,[A/Z"Z0A=LPB&YE!$>;.%/H/.@R\ .T6^HGKUN%13KHC<=(0GW[D$J$3:+(%G80WY M1/'#D^U A?P69O%X .G<*@W%$+D#H4H":!)H1\BBYA&A$CH-/AW;ZI39IK2E]7*Z:*S2R6=^X2 M-0_1.JWL+,M08C_SG.Z&(0AK/;S#,U?CM!<+3X!+@$Z!L)!;H":V0"Z:/XB M$8%G8,:.*W&?>\L ?#JM&81I'A.S">R.<9#/LK](/0^.A1O"/+I*" !1!IU! M?B59+DDHZ=8Q'5H-RMK%"5HPD'YL@OP?2/U(Y@V1H,M%LH,8DJ0JN .B+"O@ MV! 8.'!PTS$"A-TB#A(*+_1AH,,(A%]"#1M L,7@U&+4 [["4MCSU='V +N;U*PB!C4X01V-(/3Y#_I> WX$ M.AWG5X Z^;&>\4T55]_7R)L(4^392,@)3"TKFYGR1!HI,-N)?(5TD_Y7'!=! M'Z=)\EW!84C'=>"KZG@0!G50PZ#T2?DK-LN3N+2[J@[ADA5#!=-CRJ)PXO@4 M(0[1L0:V 87C*/12%WWO$#WO23:$<3[9-D_E 5A&\#T. ;$;A#V*AV*,3:.$ M^SZ7IG2LCM!B$0I2C+8M!&V3:&\9_9I(F=V$N\,@],/!! ;T%G2_/ G,B2)' M\0:&XS+KB#$D:-R4GM)GD66&,0_T&&&L&SPAUHD FN]"^$]AXGQQ=O/.G#-/ M8YWZ/T@%N9,U9I344G]F4"R[^4GCZKV!U$.C%8 96 U=*\-M)"*2FT] @2K_ M0DW]''T^$/Y-\L%S6('MSJ6%O(C?JA-^#4(*0P*I$Y M,847T-=/Y%G<1F5*ZO$8-^&F/DS,4)U(R9\BE"S8&%$8(>IH#,GO-)68=@GU M?!PE7(V *5-_IA[=6D%LP;B'\H=U-6CV W]BZD1)/7Y+4TFPC.$=,0?<(W1- MI5O&P<*\:+YD=_ 4.&'RT["#/[B; M/>L!>MEUKCD2XUY$8%%^:*'V*!/' 4 M>O@XYM&M0 .B=MHOI6Y!(OOBARSB<=3-@OS/-\3R%YV7,$#4ICIP ME30\G0\8F[, =&RC_='J.Q&2Z ML!]&I2J8 E\SFC:SX*9/(.UT-CN?KT#E^7,AS0Y%9&A$V2&2$NY+Y86<201F M$$GF<2RK3K ;A=#\7,J)F%SYD%7.=0::9#6I56I2ZB4%\DVJ/0 W;( MOI&]RT>IA-$TW%Z(,BQKIEHF8YRF2:W%R2L$$T$A1;#W/72\#8V;*S!<,HFE MHS&15GK:5M&@(XX2LKA(6N94E*(*3 ?\(.]_'JI(W6A?Y?5^J!%MX[N;TR@T MU2QR_AIM+2ZN3FN5XJ>&A^IDPY.M#1Z_B36W&2XQQVJ: &B,IHPE!D/D6X<% M?! FTL?+71$I@+F*(==$R8\W5[W(IH"ZQ7I0MI#&"%XB1,7,0S_5$'8*RL\3 M<5Z8=$E/)(HOT]1F,CD[07'0-(LX,?1O3A1I#>20X\=A)F+:T@. M^%2<>WK:H+JO.P(3;B[]%/CW'8AA$.H1FL.I;$ZCU2&MS.@QJQDZ02HS.7O+ MQ5"R4G7;8JD..;XJE2SP*; OR6='C82QR! 0J'D&4B%>RIO@$.7Y?Z M/=@W]/U1'>GG"%S$])0G]"@/* \H[%)OL8TI+IU6\D5AZ5H:DVF==:6"D1IR MRN;$H9*5DU M'/_P3L=4=?$9LFGI0E(GJ=%.6*J5%E+&B9,XEF46:*_<3M.J2/9LF \-\=/!!YIDHET4$*KI; M,/_&,,F)ND])#HIN)=B'["Q&-4.F!80R05$2HS$.!&D9FN;'BCCI/.53L:"4 M"KG87=8@R3*ZTN"Z8?);MH9"$?V5&B@R1RH 8IYGQ/C+W,+I22'S4J[YB1-< MM1B@(D[38Y"MCABA&_SS5L1"ZZ( %V#FC80R0K&,95DEI974YS"H?\FC;M_& M]0N*R-&)\SBBGT0@1ND('Z![1:IB6H5=A%$^.Z-QU#*/,)X*[&5!/W1ER/Z, M5!,TJ=;."(@QFIX:59$MHI!] Q] Q59,P99>&V4[&4$F-3DPHAAY$DK9M$1; M;FS[<$''^IE:U#D.I?:T= X[4QDM\N$"O)YS2!\,AN 5>3N3+ 8FW465O4;Z MVIC#<*[",J#=1#&BI+L&U8U"1H&!\+<'O3!)PE'6D"K7/?G;&P8HIYF)[F,2CM^PGN-^'T0A M#$ =! !'7\XS4[/CS&6N@K@;G2\*PN'Q;5 MY!+MD;6N#; M2G&>*\#L%66J@NR[UFK?&/4N+Z]+]* M2/LEC^/7N(D0%^6<;"]A'B3=E*P_B%<;40#2E&2$_'N#_H<$,7*"ET3<>@B] M3[97(W2^]*\1?E0'>%';DOU2U*QO>#:M$#IS0%YI\U]T8[>E#Y9BU3;U 1#$ MO#"E%)>GY3.LV.'MN17M6K>U,]7265JUK.IKO*(IS/(QN*KD,AY>BHT3?&.B+AX[:_X$9JY@RAPFMT+J@^'+VK:.WH6,$ M #X=45IKZ'X? H-X%&,IG#%+OJ&?A.E$ \Z"E"9(M%$QH\H:\#68S-8 MH-8)C6W6[X5/9*U"=L QLD$[=!?3I8@PR9LA"&N+*&>)UD.-C/^\'B>_%5I7 MV2^P2BU)T8:=/(70;%>H7,T0!RX,D7TTX!ZLJ$O9%Q-\I%B1O/,<_Y9K1-_@^PAR$9/N;Z>?VXDIO?*5$ M6OR!04;0LMFJ]3@2([D_=82TJQR*A"5W(3SY,S2W2XD JD[2+*-K9KOR(3LK M+LY@+G&^)23".#NE2VC$7W"/KH)]SVE/,/N(KRE(:6Q$*0C:*B$[6CO#G&3< ML:"7TVCWMR+#J-EHXW=*JL/XI=ZCI?=L80_BM/>G6D+'#2]ID,88U,VY%"%" M>GP2ZHT-:NLT 6.09S$BP?GN,X^H M\\,XEOL",-[K22Y+F9^'BCT0U-RX7N.V4>'I>X,K(W>:KFR%!O S!4Y3/^N\ M$D-VQJH&>JYVA#NN7/6GQ%1ZZ"HIH:S?4:@T.PXK"/5W+K-:4O@F1N&\P/4G M:)>/D^RD &I'+S?HM04*".'"E$QES0,+6=R_V:C3_FE<^\S66I$LN<,H#?(R MN!1>TL&IQD5Q*_^"[FPYT.?G,"SW<"@M*)HHJ"9YMMDL%XVPF%0ZILH4CGCIAGYHA]G*7TC M>:$+62;:S CZ.@>J WUTQ=@QMKB@^P:&1<1ZDY)QP(1:@-+K4;*_9F9.1C^E MHIN4?>SK!6BY)SS*$R"E7P>=DOREQ,XA-[DM7QM+9%,=HZY(CL%?>8)3"3OI M4TD#_P$S)"]6$AO^*5?NC)X;'#&8@!RDQ'*=NDO5[8%H%F"?7^Z$7#'/&,(- MY$JM$D2W G2(/3 MZO@U2O3'_8 _Z/2!VAPT_:Z2Q?4I!<9G9,U8#YC'KGE/JR3"KD#BI]BE1A M@VHN!;O$93%[;B,);,:IN"H?0V>N24OC:46KQ#?@ZHP8Q:H\'C3D_M8C*]O? M7TEG^PSR0ZHIW(+/G '>S&=$G0K,?&V(Q<4,T#(FXYD\ZB@V2J%5!_^H249! M8;+03 M'?7PK/!Q*(^Z%"@OLJ??07;$;"1??>WI(O@&U4W MC$%;#>C\^#0_/QZS&N.2Y\KKQW$R)%R= V?P"IQ0,Z\7]PO*4^<8NON#,)J4 M'A%'%<^DM3Q$#F0VTH93D)J-57.05ED_7;B4MN0:RUK;=$-D(#32:JW\W@(=^7Q;6'V MZ''.;TK9$=#P&KV9N(E%FD7:V@FX)%?40NWI0RV/U-K1?OJC?:[7K_''CG3+ MAWS5W$+NZ4/N8Q:>*%ORV7Q:_%;^'<"+R\RJ)XUW18%%L4 M6Q0_5Q1;7\+BU^+7XM?BUWH16SJ38]7 R^9/E7C 40R[$ZC-GUVQ7G9L&;@6 M+18M%BT6+=5ECT6+18M%BT6+18M%RT;9\U36Q=7^S)G#;&T\98>"L2P=58Q; M6+18M%BT6+18M.R>'18M%BT6+18M%BU/8'5NW=._XG'8I_K<:W6D!AWUN-M) MH8V6;/2T^F:MVVU5:EW!?"JFI9AX6?A9^%GX6?-K@6>!9X%G@6>-;B; MF.@O>^/;%B_#RF;_]QP&N8$XP,(-ZKN,I:WI.KS-1]O6=1W>NM/ON[5FN[TM MB7_XA7B;1Y*%^5.&^0[,FP6[!?MNP/ZBLV<87T.?7UKWQXK*@]R?UNF>28NU M"!;FUOVQ8+=@?_HZ?8>1K/:\>G.[D-? M7@PMS"W,GXUK9<%NP?[4(TOK[G,5(TM65"HO*NC^-/=,6JQ%L#"OZ8H>W%X ^ MK1UW=F839S!9H746*R]67JH90K-28Z5FSZ1F=[&X!PK+/L7BK,Q9F2OW[-HG M>R9VUD99>=F5O+1KW<;.PB967JR\[)F\[#3,N&9Y,<*,KQ*\Q==@DO[9B]BK M["/C.7VOANGM0>. N=SW%;W9W_'8CUB[66.M1K.[%JEZ7,1^K6'Y)P3 IXB_ M,^_/-$ZX-PV[G1%T'L9)Y67 0G$#(_\MB#A\^,\*@?%71P0+#BRP:+1HW!)) MEV$<+SH_P\+Q:<+QPA%198#XF^.GW.+P.>+PW(F'E<&A$WBL4@1]^"L5,.;P MT*KI9RD>'X-;'B>C,@#L;HIWZPB? EM5H:@?1NS&F26H]VWL-JKQ&L*L%LTZ[6N=_VGLY+'XKGOO8@=W)UG+Y>HY.42U;GTT:+%HL6BQ:*ENNRQ:+%HL6BQ M:+%HL6C9*'N>W0+Z);_E/FN^?DR(X&D&7G8H0.S/I"WL1NQ;;3EL>Q8P^IZN];Y]HW:ZVCK9V';X.Y%GA5MPX6?A9^%GX6?M;L6N ]0>!9 MO6?A9_5>!;(!2D^#JW:* (4(G $/W,D6P@/V7NAUB'E5[X4^KIV>KN=JB75 MR5Y_;F&^$9CO[#9C"W$+\>U _$5[SS"^ACYO[3I5*RI/2530Z=G:4KRU"!;F MSV;AWX+=@MWJ] HFO2P;YMK^3<(KB.'.;A)>50PW'S9>EQBN/;#R"' M%N<6YT\\H&0A;B'^U -*Z^YS%0-*5E0J+RKD]6QM/=V:!(OSW>!\JWN8+,PM MS'<#\]-:JW/Z1&"^A5A2I_HI4U_#Q/&WY=MU]B"P##0R+TQ[/M_1TNW&[DI9 ML[4BLSH*S02HP5&"LP58JQ65FQLK)GLK*[8-T#A66?@G56 MYJS,S7/H=I8\;XV4%9@]$YANK=NR$R K+U9>]B .N69Y,>*0KQ('F&HP2?_L M1>Q5]I'Q_#&!0WI_QW',L*^^IQY1?:^92*!W;K&C?Z9Q(OH3V2&LZ\QUH<,) M<(==1V$ OUV.AS/-[+G<):%3G%\357.;^QBPOZ/X^X)Q)V&<8QT/KB:S@6+FNWNB\/V5>@8IQ&XS#F+.P# M42)FT (0Q9*01?RO5$2<.:R?5>Q )0D;<2=.H5KF),P9A2 ?_X0_W#!. .ZQ M+-V#JB,> PGR.^QQP.E[Z"CC/\;7](;<=\AML!WSJTC M?!2%>C^,ZK'C<^;QGGGD%XN'8>I[6&/$7513T, 0I&\P9$[ '-\/[Z G'(8Q M8J[9$#(C[SWO]X$:<2L_%-"'2(R@!NA)$.!QXQ$?8[>!KC&\"F&P>GP@@@"? M.'WXG+WG@/D>_ "O%X?H])#]#KP$?G+0.:GJ%#!%C,:.FTCF#U+A$7UWPO?9 MT $"PH"%:60, 8P6]!4>(SEQ @BA<\]@_$*@Q<%7\>%6(+U]"?KD1.YPG@C! MT&7BT#BML?-P-.9!3!QA66Y_\PU(6.A^+[Y68G'NS[('C3E2H*A>N>.M 3"8.HED(%M%\#A.O&0]0'_ M '6C5Q)I("\%R.Q$P>*(@/Q_NK1J[!*6<*_B3 M3FL>DELFDDTPM+3*1U QX*M()M(0N.$@@"Y)5ZX>]NLI6 RR!1)_/K;-?.'T MA"\5,:(07O8K7A>\$Z&F4+K!HTU77J'\Y M"]DH]*1NB'@2A:07D#HI 6%0H]H8=R)_DCW$ND8B(4MH[<5CY>=S>"O'%L;U M:,9DY/0@DI .;.MQ#FG1^\QF-K,5R^\"A+^O/&YQ'ZHK>B$QDWJ"'F=.HQ.;/5F]!VCFX0./E)4TOCEQSGCL$\?!^93\%YI2 MU=4'-*=I53V7;L2RG4( /A.U+ \$E/#N5B^%RG@<9\RIW5]8ZL2"KB]S";2=-&S!LA:@ M*S7Y7-V/UJM8Y2'[ %I<0!4XW)D;%N?:7-)A0L#)?,2<'CD NN'Y5DS:!C09 M-,&!AE+)&Z /.G LZ0>I(EY(:CSAT2B1E0#CY& C4+=VS>;:#71;ES<;NYH8 MD(_4N7=:T$%_=ZUJWE3?7_@M#U( 9!2.8'(1@%N/\P"R\>= +BBO*"[J::7. MNPTY&5?SSSM 1ISV8I!MX#CZ!B@*4JP*7E^S0>,L?[? DXOUIS66U0Q5P7C! M?(.T#BI+2:9RZFB$#35"TJ8+']4VSJTO.1D%WBQK- U?K5!^A,$($7C ^&A2 M1]\+IT>EO<^<*!4I0#<4.?51E9;LR*3UG+PZ*>*'\!'#.*#TYZ;TEAMQTEXD,O70:]4YCO9Q]B+MQ!=1&@)G,B7^O;</;H7+*2+E:KK)Q ?:>"E?ON_3M%U2&,3"4TH.2\K)/KY2 M5,GHE8YST4.?7!1XXPYQXD+Z7IJ*&6*D^7.T 91UKF[U'CS#.7[H#&<),Q<& MJ+"DD_%0^KIE],U62'6[VSBM%M5' M2_#ZY+C5K1;5W25X?=KJKH_76(C]SR=2#?^[1I3_<>&(B-Z_FY#Y.\?9U]D/ M$?^!UYM7LG!\E-%6.)]L6AK7RY-L-^QK1,N2$W>3K?QF7ON"S"(U]]BBOJ 9. MZ3C%RB_!I_19%RY^38ABJB%[)SM#+YJS57R2 MB[7HK5Q$-*=T)\7RQA=QQK>E1GZ[8UZ],:WX\+2;IT?;%LRE1D1=VGV10L7W MB>S6I%$2A/3LG0Q6=I!+QK-TW+=FY/=XD)LP]]JZB<5C\W_-;]8K,[,/!<(6 MS6S>@_>\EUAC^R"GS1YDQ/Q77)+NS) M]C3*\K/]K?%[!V&#K7)XH^IXN0CN]C7* X(06\.XC2\0+W"!YG=*)DQP">X+ M)C#6V.>4UIO@G3%LYX[ORU5V52#.2L3U,^]6Q/!G]BH;T=DGTV.,=%SUU7=7 M$=4H*;CJY^W+YM]-='WJPWC.R)]A]N_7R9@3KU4A-3JE+=)WJANZC;)!:)J# M\/'SQ<$OK:GYY>/ZL\SX?/C!(U?$G%U'PN7&-YL<$MTHM9F]S.AN;GL@VN9 MM Y^.3Y<. J+NI#S/AR-1"(7FBF!/*0E1Y!=E(07G\.$L\[+&;;EI5 4"V66 M6U#\$8O7@?#?'B11R@_8JRT25+Y6N!1!AAK^'UR-9;0<.XNJO$A>(EN]+2&H MV6@F84;:+V4)4@L30/*,D;6<&U6RJVK^5B\:%&9DBC"3:S B[ MNWP&E>NU$ MR02,9;[3X9[,L/D)Q!O:\S:WP=^Y2FW'7("PWZ=4DC3P, ,BT O_8-[E1Y0= MXV!*082[.R*9*"(BF<; KMPD5+G(QY2?8.35<[4E*H@I]<"!KD0.)=O[(N!J M5Q4&,F3."X]&.AV)FKXO?[N"W$2Z4[GG#/-P1.1&3C^1F7/_:(&_=GN=;&9K=-\9/>)7]=?S&^/F24F2RW%+@)OIN^(R/QGXXX=Q(Z,(=!1,: M$B'3@#U,<(G"'P*S)/T)^ZEUU"*U]%.SW<*QQ %SH#ZN4FLC+D:]-(I5#ET2 M$M%>&NETDV08<N=#P?MH M%=V4TG^N"(J1]&CIW9DW$H% U!0_B"2W862< :7' "P#S(%2G4UO=1$-@09%!MF0A" MAKT=I2.HP1EP,X%1Y6,/@-V$(.R8(P+H!.6[H>AD%D;F[<4J+0['-4XQT!CZA%=.I L=(I<;'T [\@[\X5/=9$2#US- !5"GCCQG!7$19+93A M2?9_B?RD^VU8P3K21BUX6).[VK*,ZQ?(1WI2:J_#@/;?W= 7'V61)6SUK%MZ M=-+L=$Y.3HK$EU2_+:I+7)Z-4>VDR3",:-_M*I2?Y<4>Q/-F0_WO'O+S-K;= MA:4&8"U= *G#HP-2SGYJ@%O>:)*FHBZPO#!:S$:M(?^?=3LIT_Q9#J1Z"F9 MH0S?AC#_QCV1H,%?LZ.3&D"H!AC*JH1/9I[6EF_)-#CW\/^WAV<.SF/W;\5L M(&>4V96F--K;?B749WCF=&$=\"#,S]&'5 M;LP7>)K&RQHX890!_M7Y46-G21*)7DIGM> $ ,88O*B2?N75R=J@DJL^5+$P M0'"__-?;)Z>GTSI@7EM5Z%XWZ]XRJ<7U$_Q^]>Z!RQXD4;:=5)TN\D7$WTE3 MRUTP^*=4\=\"=9 #AC!G>V?4AF5D;539OD9W5CHSYW'LG+=;<-MQ")Q1NWI! MB'[P?$6!ILSC") 70<4P<18T?U2'V-S!S-/YL[#E%.:6B4A2.5M4)V]\ R1# M"=+P>-X&H]TIDF5R4Y Z&$$V!U6D43[9N^"X^<@'+X(VG>!I/FE$^U/.PPAJ MDEO/C"U6[U>),\!\?>AXK)\&N(>&=C;=P>P=I4^28=1LM/$[!UM*&TA[W!?\ MELN--W=RFTV<]O[DN)T&YO_!!.I*8YS5YER*$"$]/H%)MSSY0TZYZ;$#*Y= ^'B08 VN1X,! CZA3 M1PNI+3Z>Y'*<'9)2AHJE9LYSE4.FCM[).%X?]X>J$TW@XQ(UD[^D74"3_8\B MKZ1GROE4%?WQ5>T1O/=(&K6%C9NG %&7?A-1P)/_8O\);$%H&S*MYB$1B"6X MK9-Z>(=Z!_<""T^ /B)=XOLR,B/X-3N36RCS,\"<;)MF_4LX>:HV!6?_4>%Q;W;I M;'0E%ZH(H>R##K3H;BIEK;2QTT+2+=U MKX3<@[7/V;$T"_J4?_@@J6@M0%Q>_8:)748\6LW[^;D4L7B61C["M>(2/\UQ M[UGHGVKPW<2H:F]7_N>Z.V<8M<0%0;GPC?[,63J +W ^T/.B>EG;2FV6B*IVYT:WE>C..."Z+E:P0F>\>N:[> MG2(PK_CQE*R6P'"Z!"5YE(86AXP[ _1. SJ\LL9NC(L6KN5%"_&]FS?RJJ_Z M9L6J7JJ6*GV'=>HJ]RS&L_+NCJ/"[@YY<08QH,#\JBS,Z45?1UTJ(6A%%A-; M,+M\*ON?UMHP72%FKMSYAY$MX\:$^Q;J*/+U0>;)?\Q:N896C,L5:BR4X3)\ MKJ\,P4QM6I.C'0:W:W@H\O+>O*AO@EBYU6'0Z MQA7W9J?6;'5JG>YIEF355_=FF E8^9F:DCORPH%8'6B)3\8I^&V4H2YW'IKW M1WRY^18;?7LIS\BF S-IDXLZ>[K5H7.(@8"B$UAC[=-N#4IJ$B,^4FD5^E8? MZB'USH@T(@\.[TMPP.>S&0Y4#1Y'JOI(YZ4"KW#3!EY5 MX:X"20N=OMK'[< RJQ W)C0/NZ?W4C6==M'%KX!'E&D1A+)J.4Z*0MS7""R> M>Z3VMF6)9%TIT,+E+'J;DEK?IE-O!SR@C!4Z9;ZX$T5_CB'AGT[:;;6-IM9J M=S)(/WAS3%6858YXVN849+N\E)1)GN9>7RES(V7-DI VT>!^*%V^(+<(&,BI[3VT;?]Y'$;VE2&YRU#=T8R!V=:#N21NK1;J[ KJG5X MU)$C<]AJL EWHGC!^)1XKH\SNYEG\,&)\$3AF%U#=ZA #0V5<&4^MO!3J&W: MYNM".OV6"IP%GOI\-7]F>KMNO7'8.,X[NJ"M[7;D7A>QI"/-[CHZLHCJ9YGJ M-,NFJB@UB3JNZ.ZZX84H_T9G.LZHFB [ MF"$LY'O+&J2Y-G95JL.^S51(A?A5R,9K"=7M,HOI*DECGR$(:\/#-Z0"-Q/! M\GKTK0&8-)8Y;2:K5'XEW6>89W*9[0JUU)9 MN=-M":6\0##S8XQ=-TKE3791Z/MJ)ZRT7,J2S>10?U .N%+PE_D=-8]/F3%Z ML*B5+?=AN=2D5NN!G?A]&J_*OCOZ2C$ 95W.WJZ4]S O648W>B,O*\AMKVF= M/X>!=$GH\(OX*_K5YGLTVS!__&^>Y'E?UT3%11@95WXL3ELKGJZ1$8==D3U1 M*3B_7+?^N_NIV7D_R[[M]&2UL?@";4;"E4GB."R8,0X3+O3G7N[GV.1=HAY1 MAZ [QOBT/C5;NQ\?W2Q3[19"16;5E-&D/&_9^M2=HM N>+T)RULNQIUD(;4G M K1YH(6O:L.?UR0+$<5?@6"M+)8Y^>;^\5^4TM4^+E5]6^]J!I-ON,C:)+S.1VK9D-;;K<4,]7PPLR(6&*NJ5A-KJ4#:EQTAOX6N6W94_Q/#M? M[*J??6]\+AVCYS%168)[59FY7.31.A&K6R6%RTV/&ASNU%='SN!1/KB>B??T*:0=5CE#7G-!@+SJL:@'LO*QG"6()@Z,KIELDT,"M=&OM!G'AH]?2EWFN"I).'=;/MA M#^^YHLF?ZJ6JI%VHQ.R@?-\RWP-O$B#BGUP?M.()4*IXCQ-=R)[_-=.:"+(> MAKGE7<",RD02K]+I/6U*MN0V.]HR3J?DJ/M6"=+\K]3Q:;7!"-#5YJ#I]R%@ M&@_M40$_XS,ZS$?S7<$>8.U0S3!Y'"D;H7?^Z9V 91(BQ2RE0#&Q74^1RWIG M+DZ8#"<[ MKXVJ"\YFC0VB,(YI;@R MY;:)\QR6W*IHSY6HZ+D2S=II9SV1J:V>*V'Q:_%KC QMM[,HWCD=%L46Q1;% MSQ7%UI>P^+7XM?BU^+5>Q)9."EPU\++YL^X><$#<[@1J\R?JK9<=6P:N18M% MBT6+14MUV6/18M%BT6+18M%BT;)1]CR5=7&U/W/FB@T;3]FA8"Q+1Q7C%A8M M%BT6+18M%BV[9X=%BT6+18M%BT7+$UB=6_?TKWA)SZD^)DH=J4'7N^]V4FBC M)1N]0ZM9ZW9;E5H7MV&Z9P&\JJ9E6/A9^%GX6?A9LVN!9X%G@6>!9PWN)B;Z MR]Y#O<4K>K/9_SV'06[A!MZ9#>J[C*6MZ9+NS4?;UG5)][K3[[NU9KN]+8E_ M^#7=FT>2A?E3AOD.S)L%NP7[;L#^HK-G&%]#GU]:]\>*RH//&ZQ'#=$>7CVO'I4?7%T,+< MPOS9N%86[!;L3SVRM.X^5S&R9$6E\J*"[D]SSZ3%6@0+\RHG+%F86YCO!N9[ M$E.J2K949Q?94E3KUS!Q_&UY;)T]B!L#C'L!Z-/:<6=G M-G$&DQ5:9['R8N6EFB$T*S56:O9,:G87BWN@L.Q3+,[*G)6YRK_O MJI;/1.#!G]AU%0=^SUT^ZO&(M9LUUFHTNVN1JL=%[-<:EG]" 'R*^#OS_DSC MA'O3L-L90>=AG%1>!BP4-S#RWX*(PX?_K! 8?W5$L.# HM&B\8MD709QO&B M\S,L')\F'"\<$54&B+\Y?LHM#I\C#L^=>%@9'#J!QRI%T(>_4@%C#@^MFGZ6 MXO$QN.5Q,BH#P.ZF>+>.\"FP516*^F'$;IQ9@BHG(T_@8J[BV6S'AS@(Q6&I MRX=SU;N]UZ#*:P2[6C#KM*MU_J>]E\/BM]*I?!;%%L46Q1;%%L76E[#XM?BU M^+7XK01^]]J+V,'=>?9RB4I>+E&=2Q\M6BQ:+%HL6JK+'HL6BQ:+%HL6BQ:+ MEHVRY]DMH%_R6^ZSYNO'A B>9N!EAQ*T+!U5#'!8M%BT6+18M%BT[)X=%BT6 M+18M%BT6+4]@&6^W\\1/:9(Z/NL#>1N[$=M&6Q[+CC6LKK=KS>U=+V3#?!9X M54_KL/"S\+/PL_"S9M<"SP+/ L\"SQK?@VF&N!5W7K8.%GX6?A9^%GS:X%WA,$GM5[%GY6 M[U4@&Z#T-+AJIPA0B, 9\,"=;"$\8.^%7H>85_5>Z./:Z>EZKI98!Y3L]><6 MYAN!^K2W%6XM@8?YL%OXM MV"W8K4ZO8-++LF&N[=\DO((8[NPFX57%ZA\G"W,)\-S _ MK;4ZIT\$YEN()76JGS+U-4PR8KNPO6/5!8]BE89V7.RMP\ MAVYGR?/62%F!V3.!Z=:Z+3L!LO)BY64/XI!KEA%.?OG7?V'LYW^KU\^= M>,B9Z/XSJ-X[/V4VV.Y*=>7^F<<(]=A[&28W]&H5QS+X%$8?> M_1,>_^J(("YY?@E_0W%L .EB1!CK3=@-,$7T@9-!PCX&MSQ.Z+RF\J^((T1L#Y=TXLXJ_ \'=^Z'YG+@ $_OC"^V\/ MW%:C>=QH-II)2+_:[>;!+V4(NR>".HW M8=ED;^B/U$!UR&'PKX?WD'/& UX MS.)A>,<2>./HP7!I, ;$]#1G^D .QLQS/Q^,/@[&+0U&V&=A&AE;87%X8F-X M1#X\KAH>YL18[I,3N4/6;M88\I4J?L]=/NKQ2#_M'DY+H/&S%[%7TT FR<0. M,Y?[OA*KMP>- _H['CNN_ONA7-?2W&C\+1_&9:+[JZQ!++0P2ZJ>M;8)*@<8 M"(VT6BLWN'"U:2T20>_O.-H(;-J?6L1R 80\DDT5P;<6/?^X1::UKB0](:SM M/]2T]2M19=MH'FUNY?%M8?;H<<[]IAT!C;PXBS2+M(T3(.<%%FI/'VKYM,^. M]M,?[2R<@#]VI%L^_)4*X",&.RSDGC[D\NC1S'!O:WJ@0V=0*-H1#1BPJSS: MG\!Q])F6V]3J>572H'>R@6ACBQ2[.B?RM+.U%;N*Y/9;_#X=_-IC=BV*+8HM MBBV*=X]BZTM8_%K\6OQ:_%HOH@K;6'>27%F5),^*G":X7G94\0)+BQ:+%HL6 MBQ:+EMVSPZ+%HL6BQ:+%HF7=['DJZ^*7_);[K/GZ,3/_IQE/J%5/R[#PL_"S\+/PLV;7 L\"SP+/ L\: MW$U,]!]T,_&69O_?#F\.F3/@@3LQCA?<5!S 7BJU#JFNZJ52W5JSO6\W:MJ[ MTRS,JV_>+-@MV'<#]A?[=N?K&OILKTBVHO(P]Z?U5.[4M#"W,+?NCP7[+UR6&ZXXH']>.3X^J+X86YA;FS\:ULF"W M8'_JD:5U][F*D24K*I47%71_FGLF+=8B6)A7.6')PMS"?#-ORV-;X8+LG<6-5[X@>V_.*UW;!=GK[O%I[;BS,YNX_ 79VU]G ML?)BY:6:(30K-59J]DQJ=A>+>Z"P[%,LSLJ'C0. MF,M]7]&;_1V/'5?__= @HF93H_&W?!27B8JN$KM=*+J[O:IZO^^JEL]$X,&? MV'45!W[/73[J\8BUFS76:C2[:Y&JQT7LUQJ6?T( ?(KX._/^3..$>].PVQE! MYV&<5%X&+!0W,/+?@HC#A_^L$!A_=42PX, "BT:+QBV1=!G&\:+S,RP'. C%8:G+AW/5N[W7 MH,IK!+M:,.NTJW7^I[V7P^*WTJE\%L46Q1;%%L46Q=:7L/BU^+7XM?BM!'[W MVHO8P=UY]G*)2EXN49U+'RU:+%HL6BQ:JLL>BQ:+%HL6BQ:+%HN6C;+GV2V@ M7_);[K/FZ\>$")YFX&6'$K0L'54,<%BT6+18M%BT6+3LGAT6+18M%BT6+18M M3V 9;[?SQ$]IDCH^ZP-Y&[L1VT9;'LN.-:RNMVO-[5TO9,-\%GA53^NP\+/P ML_"S\+-FUP+/ L\"SP+/&MSGMT[\[?#FD U"(#[ TP)8S-TT$HE8=+Z/C:GM M=:Y]L]8ZVMIY^#:8:X%7=>M@X6?A9^%GX6?-K@7>$P2>U7L6?E;O52 ;H/0T MN&JG"%"(P!GPP)UL(3Q@[X5>AYA7]5[HX]KIZ7JNEE@'E.SUYQ;F&X'YSFXS MMA"W$-\.Q%^T]PSC:^CSUJY3M:+RE$0%G9ZM+<5;BV!A_FP6_BW8+=BM3J]@ MTLNR8:[MWR2\@ACN[";A5<5P\V'C=8GAV@/+K5JGLP=R:'%N;X*3^+8Y[$G[@3IQ'WKH(ON-DQ B+?.;&(OP)M[_S0_?[+O_X+8S__6[W^ MJR,"=@Z,A4]P=V2-73L)#Y*872#![&/0Q]+<8^DX#&KL MOV0O#L[&8Y^SCP MOYM\=A+@Z-D/$?^A:50D7O5S B5Y?^0/L/-42'$,./,;,4OQ"O[^D)SY^%FW MV3C_C?@#["'6?)35'; T$)+8;_#^@'G<%2/'C]\>?/Q\XVV@U.C3 ]&M7 M USQD5UV;#:F]=<]Z*?MAAIT^/7LM/G'T1C< 3H*$0D<3',[ M__PJ>B_B<1@[/G !BE$I6>@Z](4[R?R'&9X?-YJ-)O'\N-%N-P]^*7/F[EFL MG';VUK("2N_O.#J?Z+3YGFX'ZWO-1 )NFEOBL5'C"[@X[6,:/WL1>S7MJJUS M,??/-$Y$?R+)O J8@_\$> 5&#YV\&KOC3.""+GP$;SP6<1?\=2;R'ODA=")F M(-P^=LRGCCG4,78WY 'CMZ0VL+0[= !H,0/5XHK(34=QX@0N/?# *TXX2X9. M O_BS'6B: *P9,X(0$J,0^*P7C;"80#G.V$]3A2!5XU.[6'N_[(O^K'P13)A M(F8CY"B50 ,]=)QZR MOA_>Q2P)J53$?2HA^YMM^3I^D]-_B[ZT2=G'/HM3=ZAYY$!+( (QL!F)@XJA M4Y*_W*M1*P:WY6OL\R" ,?>F.T9=D1R#O^Z& AJ:PT[Z5-+ ?[B<>S$]&D?A MG]S%3AD]-SAB, $YB'7VHW"45W:F6,\1$_D.BD@P_+B$H#W4K8M-5N* MM%R-8=!1P<; J'X(1'_X*T4$?.+),$2[=1_#MC)*C0MCZ!;2=-YVW_(X:EM]1W9]$$$9 A*[R#+6N68ND49)H M4%ABC[1N[))N+!B EFD ZNV#7^HG\!5,I@W&;X]V.UXEMFS!>+5/3DZK,EY0 M&0/9=$&_H^C_#PHB(TF<<;*RUO/O]]^\EYORSR$8J38S-O<60%D54_X[9T,' MC(,D+8&AY#_&/(C)'__IB(SQ3\=0?T1Z.QE&G+,1M#8$8Q!XH/$_.1&8CG:S MQG"DJ !JG1K8GG@,]@'TM ^3 @>L #Y*?;(I(Q&(43JB%L?.A(!EVK[W*;J: MTVTR0+, 62]KF5P0[ O:GE#"'FI07L<+/1"MQIO/5Y>9!6XUW[Q4U@_\72R$ M]HSW>40V%JA3E@\Y 6E?:S#7W=.Y!5(_IU,XJU TM"6RXF,XX,%E+Z+,P#? M.I9>"Q)9U@P,A)]ZNNL+"2FCX[>RMC/*L'B81O<1$(&;()T$9PSE?H#B26 , MV4_-VO%)5T*B76MW6H^&Q8P'L"LQ^"@]QCC6G <>^.*?DHT UQ).U1C4Z0PX M>5O:+R-/%LI'X.B3QX5VRA??D7W@L0;DBY+K&J.\C<-(MA#A6&E?JVQ8[@2\ MSQQ9I(U[A^PK? T"10,T3?*\FH JCX\Y95_2E)R^5.!79947!Z706];:P?:=0Q!9\!\%+KD1!-P"?O0-"?L];@LSKT4QAW=;_:.$*;:=FX=X5-# M8>]/"0V8"^!LPN4%+O>X+V"2$"]D[GT2!J^GL&GRMI_Z4)MB)9%ZYN)$!CJ. M6LP@9@@:;00"G<#_T;&GHF6"G\F]@-:7IDH.;EEU*/@"6U35WB?-=ZAVBT+< MZ=9PV82DN-.1OV=8@F_?"!_II567W;)IZ90D 17T.,@ES5.P.S" 37F(< MIC0ZS1^+'#L^R3G6;>+O:>,&-E.0;/3X0 0!_@+):#5:Q,E<-\-K@"F]:G9) M>Q)5M?R+11Q>/_NFEH(V'CL M") )]R)I#%K-1K2SU!#0!/=."55@--8_@.: M":04J(DK':U),$]!\: 32Q7LY@LHD*9KC MGNE6Q CE*Q(HGA1JB&5UI:3I\(F*ILPA;YF PCTSD+*)S0?E#;]X!P:R+Y*7 M$O->N_A=<,TF7D 5=0A5X;+RX M?;QHZ*<:W'Z/5HVH/KA'7Y1O,G8B\$/'RVJG]RG_&JJRUU#T\> #B5S4A=DV MM]&-QYC"%7HP!UH?1F,_G'#.= ]74AJZM"J\3OW9/FXM&*_YC5>FTZM"M'VR M2$$^O-/7$2?733O!:"FN*!HW)PMAIFU5@Q9U51'H:*I&UO+(<6^>+%(TRQ!1 M45:L:"T;)^MEA9H[2K>]AI/ZV7[*;Z1SINK[' ;9W/\S?^SUV:\\&N'$'Y= MZ:VL3M5F5I95)6O">J[ZNI;%BXG7S<9_YSU\6"MKZ_,_6L;R-;O M+G+R_,\ M5^U,1.PKU!GC@H&,A.'B[)@^GY?1MAG._7%.F1X1N0F?G9',3?M'*Z9"OBW#"-VR[C86KC<;]7;3[/QLXTMW M;4- >P [=@(C:/VHWF@NS\]+/G!\]LE)$ES;0R-:2.J\-]F!RJJB0'&AX)/. M>C@N9#WDF:Q5B8S_KE:' A'(6+COA]&WT$S /V*X,6M MB 5F1B.\BG7*JJ#$V7C,P3IGM5ZHA:US3(X422&]X=O-^=G%N9G@L.TUB05P M*0S&0S+\JP*DJT O.H5H*+!\-!Q#&&N!Q,#X#19GTAT1>G/CRYXSQ0J0M -J9@J.R"6&<#G$/5/CMS2:V7Y\JS%WH\;F.=:\^3 M0TRO?RD!BA6%P2!$2DHK+(Y57F') +^4B]PN<0A3*/ T,;G.@TDE=R%SJ07' ME?T BP!\>'2KU ^/QS"@U!C(CR-36L%H4O(NEX3]F483EM 2%8F\B.DEK:H/ MN4\K97]W@A03'EI'" A&"^@])!U#',ANC3?@_9BB\H5CO5CAH5(_TY5HWAF'-W M&(1^.)BHW =%ODR)PD7 <*)7*E7'DQ#[WM/))" JW(E\ 4R2M1;UN!(@5 BKPF@8.)/E5@TBCT1!^3/GZ[_@P J[\G&0<= M\0E<86<@Y_<7CLN16ABGZ%;(;'F]]V8^Y]4R=WF[!?XA[#%7II_ZAPPSICR/ MUEUQ&#P.H!W)Q7%20C16$Q;>R4PRB0J" QK22.3 H,IK4KPRR/IQF \\YO-3 M9D VTHGB6H%8K2"7XR%;DH?D*K@RH59"3M-]'U/EP([#.*E+!3($9")QIN[X MY.1ZX[&J ?X3?7<")U,/I(C^GOK0Q*G60DFF;;5Q80$ F^Q+C=TZKIP[R"'B MMY1,02]C0SWK(495&"O0?PX/)?#=VWH'%_O?@V_+$WI^%JJ!X656S=8&Q(KHS.&0&A8BF)+J$LJAB#E,02O21]BWF2=9# M^@;&#FT2#8)).HA",I2B&W-T()4D4 H0CNX-'R$<**1>SF) M-"PXK$K. H F(J,70EN2=I"2GNBGD2OWDP1&Z0([9%J;T5.GG_!B%P[9AWS+ MC<=ON1^.97HZ^AC\KU1M)"&;+WT0O8%#=2+"M+[8C41/BD:5 MF0N8E,9ABMO5/&?D#%3VF0C^3 .9$1MA\FO_4+-;L$91%S)'HPQ^%VNC/?C M8RG+I*=26=\=-PIX,-NEO&-*PG7=-':R^4+!\!N)ZR,@(%';OWC1M-645?8& MG,+)RD%#ES$%=FI%:WK5R'ON /\P=S7P'/0#2*/!%V'@3S([,^7#*@\@=H?< M2WUL)]/3,YZ[8G2A%@F]HBG&>9QTU]M&'3A2Y:5=![P$/&9#,CAWMZ'!( SJ M10ZBMM<^D@8)I7SG&( 2=1*WS"_#C70A.K%X7(@'!AT^'H5RC)!UTGK+;E)L MRI286?\-"-/HTWI.-W7'29,'(C,I?![',&N.>Y5)?^ @T M*(CFB%V-0>G3],EC5V3F(SYP*.?=]& U\N0FGL)V3NG/$[,T\0 FVD9:YH=K M5RG"'0%<[E302D]Q1R7ZJID1=C$NSN:DC*I1@'_ATJ8"\&R3$?HR<3(C-$J/ M^$+O_B5'2)$R'3[)A@6^&0#K$ SAE$2B4D0-.)*33[EL5I-<+'E.2:[X+N.: M:ANU1).7!M:4'UVHV MT8.KC&K3\[>V%F2E"(0OPX(.!84U/+-!D1&T7 \G%RR_^G@9<6[RE MQ!4F]% 8APC:\8J-JEF"C#V3(LJG/TVIB: I^5JK(2@@H#ZI?4 8^GV!YG&P MQ.P>36=G2OV1O21+64.G8ZG*ICT=^!NC Z&.#BB@P,^)N1,^HDW^X :/8DU$ M5GWW3;,M]S.8CXZ:>52-#C@H$N@INU$@DG1VX0FZ57$V&GYXE^V3P@I!$BG^ M@N0H/U!Z?3H8$Y'EPC,5PB!0,U9R7N1>,>F=Y'O>I"J@4 $DQZH?*"E7T-Q M ^Z5<[J@V#/?0O>WI(_$5@HW)%%JT*AVQF#7T:\N8_Q1HS/->)#I0IPK"X[/ M&!TU"9YB0C$ -D5'%BS*&FR^016F[9&I<6B'8)QDU1@<)7'1+DDN+'>9J(-& M3$1QM"3_:UISRKE9Q'642795_\4#<%0#5R-X:O&HP'U#:CN:D QU!L;*0E]^ M?GQ/28NS M M%WQ7O?%9<3;SH[4'&\>A*\/VRD5TRL(EVFN2YPG(T,UL@,?4+5E0K-72JN5W M+H\B2Z,(*@9S B 2N1$@+1*EOO;5\I !5]&/7(WMTU+0<@?-EBQ.5G3Q9S;< M:4PX"/2S*SW4HXTLJE )95S]R8) 9TT> "#/IH2.P!RU6SMJM&HP\ZZQXUJG M>0)_=O#G::M90SE"),*+TT8-IN+:H^!D%LB&.[CG'2=V,D4@/_QNP6K,5[UT M@EZN5!Y9\$MZ#M?#,. ,Z!+7H<>^AGA2P!&T^&MVX@J^ D>Q4_804RIR<4=U M&N-Q%RZ&N.(AC5%*BZKLO3S(0 95@#S*_T4/*:[IY2A-'T7[Y/O9J WG(62+(9J)%]'AD%-QZ15M"I;\Z)<6!+[SG,@FCJ& M9H"\,$5 %E-<"R,[&?*3+ ME"G*'[*36 "0U3YHZGJ/K*LXH5#I#$],9&HVC M;CN;;ZG55QV?,TD+2DC)3X8B Y)W M4"R9&9GKD5)BBW0ZI54+L^Z>Z*FWN1:AZKV2TXZ%L4@Z."4=C7"HLP@D!6L\ MWL<%;([^>2T_G4@JKL(*;:S.'%;1*)2B+*2',:#,X\FB1SKN!_A-E0RIE3GE MP9B-RP2I//BL9E2YA=0S>F@%PUEJ$DE1$/TH7UQ02R 1S;1G>QZ49FX1:;BH M(<_FC&3G:BCD&DG*B4:_379/CFI6DH[[H+598SEM.F!*?5*,([E'SLCYC3JH MT2FLI^^9S^[FBXL%)F2=ET-6%*X"S_?;B6\>U9NG[4Z5/'/I ML&2**'<+U":0F44 ^4*/G*&_E::*RWTNY1,@EKY&CLS>==?7Q^@M:>8PPM^5IJ2*DF,H7-/-B VA(S"T'<:[2E4=QJ9 MIZO="Q4R.2(U:GRII@SFDQ8V'_JW&C4S\]MCF&F
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

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 05, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	VirnetX Holding Corp
Entity Central Index Key	0001082324
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		58,144,888
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017